Merit Medical Systems (MMSI) 10-K 5 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 02, 2015	Jun. 30, 2014
Document Information [Abstract]
Entity Registrant Name	MERIT MEDICAL SYSTEMS INC
Entity Central Index Key	856982
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		43,632,232
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$658,573,016

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash and cash equivalents	$7,355	$7,459
Trade receivables — net of allowance for uncollectible accounts — 2014 — $893 and 2013 — $840	72,717	60,186
Employee receivables	173	224
Other receivables	7,507	3,279
Inventories	91,773	82,378
Prepaid expenses	5,012	5,121
Prepaid income taxes	1,273	1,232
Deferred income tax assets	6,375	5,638
Income tax refund receivables	155	398
Total current assets	192,340	165,915
PROPERTY AND EQUIPMENT:
Land and land improvements	16,830	16,240
Buildings	130,447	127,747
Manufacturing equipment	145,022	136,768
Furniture and fixtures	35,201	32,327
Leasehold improvements	16,096	13,692
Construction-in-progress	21,858	25,172
Total property and equipment	365,454	351,946
Less accumulated depreciation	-121,283	-108,676
Property and equipment — net	244,171	243,270
OTHER ASSETS:
Goodwill	184,464	184,505
Deferred income tax assets	9	800
Other assets	15,873	13,806
Total other assets	310,654	319,098
TOTAL	747,165	728,283
CURRENT LIABILITIES:
Trade payables	29,810	26,511
Accrued expenses	33,826	27,702
Current portion of long-term debt	10,000	10,000
Advances from employees	381	292
Income taxes payable	1,413	1,089
Total current liabilities	75,430	65,594
LONG-TERM DEBT	214,490	238,854
DEFERRED INCOME TAX LIABILITIES	6,385	2,548
LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS	1,353	2,031
DEFERRED COMPENSATION PAYABLE	8,635	7,833
DEFERRED CREDITS	2,891	3,065
OTHER LONG-TERM OBLIGATIONS	2,722	2,652
Total liabilities	311,906	322,577
COMMITMENTS AND CONTINGENCIES (Notes 2, 7, 8, 9 and 13)
STOCKHOLDERS’ EQUITY:
Preferred stock — 5,000 shares authorized as of December 31, 2014 and 2013; no shares issued
Common stock, no par value; shares authorized — 2014 and 2013 - 100,000; issued and outstanding as of December 31, 2014 - 43,614 and December 31, 2013 - 42,846	187,709	177,775
Retained earnings	249,962	226,988
Accumulated other comprehensive income (loss)	-2,412	943
Total stockholders’ equity	435,259	405,706
TOTAL	747,165	728,283
Developed technology — net of accumulated amortization — 2014 — $27,982 and 2013 — $17,602
OTHER ASSETS:
Intangible Assets	79,172	91,052
Other — net of accumulated amortization — 2014 — $22,480 and 2013 — $18,870
OTHER ASSETS:
Intangible Assets	$31,136	$28,935

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CURRENT ASSETS:
Trade receivables, allowances	$893	$840
STOCKHOLDERS’ EQUITY:
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,614,000	42,846,000
Other
OTHER ASSETS:
Intangibles, accumulated amortization	22,480	18,870
Developed technology
OTHER ASSETS:
Intangibles, accumulated amortization	$27,982	$17,602

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
NET SALES	$509,689	$449,049	$394,288
COST OF SALES	284,467	254,682	212,296
GROSS PROFIT	225,222	194,367	181,992
OPERATING EXPENSES:
Selling, general, and administrative	147,894	128,642	122,106
Research and development	36,632	33,886	27,795
Intangible asset impairment charges	1,102	8,089	0
Contingent consideration benefit	-572	-4,094	0
Acquired in-process research and development	0	0	2,450
Total operating expenses	185,056	166,523	152,351
INCOME FROM OPERATIONS	40,166	27,844	29,641
OTHER INCOME (EXPENSE):
Interest income	217	255	226
Interest expense	-8,829	-8,044	-604
Other income (expense) — net	18	-216	-1,645
Other expense — net	-8,594	-8,005	-2,023
INCOME BEFORE INCOME TAXES	31,572	19,839	27,618
INCOME TAX EXPENSE	8,598	3,269	7,908
NET INCOME	$22,974	$16,570	$19,710
EARNINGS PER COMMON SHARE:
Basic (in dollars per share)	$0.53	$0.39	$0.47
Diluted (in dollars per share)	$0.53	$0.39	$0.46
AVERAGE COMMON SHARES:
Basic (in shares)	43,143	42,607	42,176
Diluted (in shares)	43,409	42,884	42,610

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income	$22,974	$16,570	$19,710
Unrealized gain on marketable securities:
Unrealized holding gain arising during the period	0	0	551
Less income tax (expense)	0	0	-215
Reclassification adjustment for gains included in net income	0	0	-846
Less income tax benefit	0	0	330
Interest rate swap	-630	2,992	-1,789
Less income tax benefit (expense)	245	-1,164	696
Foreign currency translation adjustment	-3,160	292	-74
Less income tax benefit	190	5	15
Total other comprehensive income (loss)	-3,355	2,125	-1,332
Total comprehensive income	$19,619	$18,695	$18,378

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
In Thousands, unless otherwise specified
Beginning balance at Dec. 31, 2011	$357,089	$166,231	$190,708	$150
Beginning balance, shares at Dec. 31, 2011		42,008
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	19,710		19,710
Other comprehensive income	-1,332			-1,332
Excess tax benefits from stock-based compensation	877	877
Stock-based compensation expense	1,917	1,917
Options exercised	5,156	5,156
Options exercised, shares		610
Issuance of common stock under Employee Stock Purchase Plans	430	430
Issuance of common stock under Employee Stock Purchase Plans, shares		33
Shares surrendered in exchange for payment of payroll tax liabilities	-439	-439
Shares surrendered in exchange for payment of payroll tax liabilities, shares		-31
Shares surrendered in exchange for the exercise of stock options	-1,831	-1,831
Shares surrendered in exchange for the exercise of stock options, shares		-131
Ending balance at Dec. 31, 2012	381,577	172,341	210,418	-1,182
Ending balance, shares at Dec. 31, 2012		42,489
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	16,570		16,570
Other comprehensive income	2,125			2,125
Excess tax benefits from stock-based compensation	259	259
Stock-based compensation expense	1,467	1,467
Options exercised	3,733	3,733
Options exercised, shares		413
Issuance of common stock under Employee Stock Purchase Plans	448	448
Issuance of common stock under Employee Stock Purchase Plans, shares		37
Shares surrendered in exchange for payment of payroll tax liabilities	-21	-21
Shares surrendered in exchange for payment of payroll tax liabilities, shares		-48
Shares surrendered in exchange for the exercise of stock options	-452	-452
Shares surrendered in exchange for the exercise of stock options, shares		-45
Ending balance at Dec. 31, 2013	405,706	177,775	226,988	943
Ending balance, shares at Dec. 31, 2013		42,846
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,974		22,974
Other comprehensive income	-3,355			-3,355
Excess tax benefits from stock-based compensation	576	576
Stock-based compensation expense	1,460	1,460
Options exercised	9,638	9,638
Options exercised, shares	878	878
Issuance of common stock under Employee Stock Purchase Plans	450	450
Issuance of common stock under Employee Stock Purchase Plans, shares		33
Shares surrendered in exchange for payment of payroll tax liabilities	-249	-249
Shares surrendered in exchange for payment of payroll tax liabilities, shares		-16
Shares surrendered in exchange for the exercise of stock options	-1,941	-1,941
Shares surrendered in exchange for the exercise of stock options, shares		-127
Ending balance at Dec. 31, 2014	$435,259	$187,709	$249,962	($2,412)
Ending balance, shares at Dec. 31, 2014		43,614

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$22,974	$16,570	$19,710
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	35,929	32,542	22,534
Losses on sales and/or abandonment of property and equipment	916	177	204
Write-off of patents and intangible assets	1,427	8,208	55
Impairment of cost-method investment	0	0	2,368
Acquired in-process research and development	0	0	2,450
Amortization of deferred credits	-175	-139	-174
Amortization of long-term debt issuance costs	987	845	0
Realized gain on sale of marketable securities	0	0	-745
Deferred income taxes	3,870	1,359	549
Excess tax benefits from stock-based compensation	-576	-259	-877
Stock-based compensation expense	1,460	1,467	1,917
Changes in operating assets and liabilities, net of effects from acquisitions:
Trade receivables	-13,599	-6,445	-6,576
Employee receivables	46	-53	-11
Other receivables	-3,042	-609	-760
Inventories	-9,396	2,334	-8,965
Prepaid expenses	-58	-758	736
Prepaid income taxes	-41	18	-367
Income tax refund receivables	11	1,267	452
Other assets	-1,388	-1,806	-1,178
Trade payables	5,326	-5	7,721
Accrued expenses	6,137	-276	4,448
Advances from employees	142	-277	317
Income taxes payable	1,083	255	2,057
Liabilities related to unrecognized tax benefits	-76	-520	-209
Deferred compensation payable	802	1,877	1,371
Other long-term obligations	566	-4,399	-89
Total adjustments	30,351	34,803	27,228
Net cash provided by operating activities	53,325	51,373	46,938
Capital expenditures for:
Property and equipment	-34,181	-59,505	-64,643
Intangible assets	-1,714	-1,617	-1,460
Proceeds from sale-leaseback transactions	5,521	24,000	0
Proceeds from the sale of marketable securities	0	0	3,248
Proceeds from the sale of property and equipment	98	113	43
Cash paid in acquisitions, net of cash acquired	-5,927	-31,600	-192,762
Net cash used in investing activities	-36,203	-68,609	-255,574
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	8,146	3,729	3,755
Proceeds from issuance of long-term debt	144,018	176,764	330,630
Payments on long-term debt	-169,392	-165,477	-123,801
Proceeds from industrial assistant grants	0	389	1,029
Excess tax benefits from stock-based compensation	576	259	877
Long-term debt issuance costs	0	-798	-3,706
Contingent payments related to acquisitions	-67	-77	-57
Payment of taxes related to an exchange of common stock	-249	-21	-439
Net cash provided by (used in) financing activities	-16,968	14,768	208,288
EFFECT OF EXCHANGE RATES ON CASH	-258	208	-61
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	-104	-2,260	-409
CASH AND CASH EQUIVALENTS:
Beginning of year	7,459	9,719	10,128
End of year	7,355	7,459	9,719
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest (net of capitalized interest of $389, $1,038 and $456, respectively)	9,014	7,877	434
Income taxes	3,289	735	5,277
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases in accounts payable	2,896	4,055	12,372
Receivable due for sale of equipment	1,256	0	0
Acquisition of customer list in exchange for a settlement of trade receivables	0	0	377
Acquisition purchases in accrued expenses and other long-term obligations	1,000	350	5,149
Merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options	$1,941	$452	$1,831

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net capitalized interest	$389	$1,038	$456
Common Stock
Company's common stock surrendered in exchange for the exercise of stock options (in shares)	127	45	131

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization. Merit Medical Systems, Inc. (“Merit,” “we,” or “us”) designs, develops, manufactures and markets single-use medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology devices which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes the embolotherapeutic products and the cardiac rhythm management and electrophysiology ("CRM/EP") devices we acquired through our acquisition of Thomas Medical as described in Note 2 below. Our endoscopy segment consists of gastroenterology and pulmonology medical devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.
	We manufacture our products in plants located in the United States, The Netherlands, Ireland and France. We export sales to dealers and have direct sales forces in the United States, Western Europe and China (see Note 12). Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The following is a summary of the more significant of such policies.
	Use of Estimates in Preparing Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
	Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.
	Receivables. The allowance for uncollectible accounts receivable is based on our historical bad debt experience and on management’s evaluation of our ability to collect individual outstanding balances.
	Inventories. We value our inventories at the lower of cost, determined on a first-in, first-out method, or market value.  Market value for raw materials is based on replacement costs. Inventory costs include material, labor and manufacturing overhead.  We review inventories on hand at least quarterly and record provisions for estimated excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. The regular and systematic inventory valuation reviews include a current assessment of future product demand, historical experience and product expiration.
	Goodwill and Intangible Assets. We test goodwill balances as of July 1 for impairment on an annual basis during the third quarter, or whenever impairment indicators arise. We utilize several reporting units in evaluating goodwill for impairment. We assess the estimated fair value of reporting units using a combination of a market-based approach with a guideline public company method and a discounted cash flow method. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized in an amount equal to the excess of the carrying amount of the reporting unit goodwill over the implied fair value of that goodwill.
	We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	3	-	12 years
	License agreements and trademarks	3	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
	Long-Lived Assets. We periodically review the carrying amount of our long-lived assets for impairment. An asset is considered impaired when estimated future cash flows are less than the carrying amount of the asset. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. There were no impairments of long-lived assets during the years ended December 31, 2014, 2013 and 2012, except as noted in Note 4.
	Property and Equipment. Property and equipment is stated at the historical cost of construction or purchase. Construction costs include interest costs capitalized during construction. Maintenance and repairs of property and equipment are charged to operations as incurred. Leasehold improvements are amortized over the lesser of the base term of the lease or estimated life of the leasehold improvements. Construction-in-process consists of new buildings and various production equipment being constructed internally and externally. Assets in construction-in-process will commence depreciating once the asset has been placed in service. Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years
	Depreciation expense related to property and equipment for the years ended December 31, 2014, 2013 and 2012 was approximately $21.0 million, $18.4 million, and $15.0 million, respectively.
	Deferred Compensation. We have a deferred compensation plan that permits certain management employees to defer a portion of their salary until the future. We established a Rabbi trust to finance obligations under the plan with corporate-owned variable life insurance contracts. The cash surrender value totaled approximately $9.0 million and $7.8 million at December 31, 2014 and 2013, respectively, which is included in other assets in our consolidated balance sheets. We have recorded a deferred compensation payable of approximately $8.6 million and $7.8 million at December 31, 2014 and 2013, respectively, to reflect the liability to our employees under this plan.
	Other Assets. Other assets consist of our deferred compensation plan cash surrender value discussed above, unamortized debt issuance costs, two investments in privately-held companies accounted for at cost, a long-term income tax refund receivable, and deposits related to various leases.
	Deferred Credits. Deferred credits consist of grant money received from the Irish government. Grant money is received for a percentage of expenditures on eligible property and equipment, specific research and development projects and costs of hiring and training employees. Amounts related to the acquisition of property and equipment are amortized as a reduction of depreciation expense over the lives of the corresponding property and equipment.
	Revenue Recognition. We sell our single-use disposable medical products through a direct sales force in the U.S., through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenues from these customers are recognized when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable and (iv) the ability to collect is reasonably assured. These criteria are generally satisfied at the time of shipment when risk of loss and title passes to the customer. We have certain written agreements with group purchasing organizations to sell our products to participating hospitals. These agreements have destination shipping terms which require us to defer the recognition of a sale until the product has arrived at the participating hospitals. We reserve for sales returns, including returns related to defective products (i.e. warranty liability), as a reduction in net sales, based on our historical experience. We also offer sales rebates and discounts to purchasing groups. These reserves are recorded as a reduction in net sales and are not considered material to our consolidated statements of income for the years ended December 31, 2014, 2013 and 2012. In addition, we invoice our customers for taxes assessed by governmental authorities such as sales tax and value added taxes. We present these taxes on a net basis.
	Shipping and Handling. We bill our customers for shipping and handling charges, which are included in net sales for the applicable period, and the corresponding shipping and handling expense is reported in cost of sales.
	Cost of Sales. We include product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, medical device excise tax, product royalty expense, developed technology amortization expense, production-related depreciation expense and product license agreement expense in cost of sales.
	Research and Development. Research and development costs are expensed as incurred.
	Income Taxes. We utilize an asset and liability approach for financial accounting and reporting for income taxes. Deferred income taxes are provided for temporary differences in the basis of assets and liabilities as reported for financial statement and income tax purposes. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income for each full fiscal year.
	Earnings per Common Share. Net income per common share is computed by both the basic method, which uses the weighted average number of our common shares outstanding, and the diluted method, which includes the dilutive common shares from stock options and warrants, as calculated using the treasury stock method.
	Fair Value Measurements. The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market-based inputs or inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	Stock-Based Compensation. We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation — Stock Compensation. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model. Stock-based compensation expense for the years ended December 31, 2014, 2013 and 2012 was approximately $1.5 million, $1.5 million and $1.9 million, respectively.
	Concentration of Credit Risk. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We provide credit, in the normal course of business, primarily to hospitals and independent third-party custom procedure tray manufacturers and distributors. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses. Sales to our single largest customer approximated 3%, 3% and 4% of total sales for the years ended December 31, 2014, 2013 and 2012, respectively.
	Foreign Currency. The financial statements of our foreign subsidiaries are measured using local currencies as the functional currency, with the exception of Ireland which uses the U.S. Dollar as its functional currency. Assets and liabilities are translated into U.S. Dollars at year-end rates of exchange and results of operations are translated at average rates for the year. Gains and losses resulting from these translations are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Foreign currency transactions denominated in a currency other than the entity’s functional currency are included in determining net income for the period. Such foreign currency transaction gains and losses have not been significant for purposes of our financial reporting.
	Derivatives. We use forward contracts to mitigate our exposure to volatility in foreign exchange rates, and we use an interest rate swap to hedge changes in the benchmark interest rate related to our Credit Agreement described in Note 7. All derivatives are recognized in the consolidated balance sheets at fair value. Classification of each hedging instrument is based upon whether the maturity of the instrument is less than or greater than 12 months. We do not purchase or hold derivative financial instruments for speculative or trading purposes (see Note 8).
	Accumulated Other Comprehensive Income (Loss). As of December 31, 2014, accumulated other comprehensive income (loss) included approximately $350,000 (net of tax of $(223,000)) related to an interest rate swap and $(2.8) million (net of tax of $202,000) related to foreign currency translation. As of December 31, 2013, accumulated other comprehensive income (loss) included approximately $735,000 (net of tax of $(468,000)) related to an interest rate swap and $208,000 (net of tax of $12,000) related to foreign currency translation.
	Recently Issued Financial Accounting Standards. In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2014-15, which requires management to assess, at each annual and interim reporting period, the entity's ability to continue as a going concern within one year after the date that the financial statements are issued and provide related disclosures. The guidance is effective for the year ended December 31, 2016, with early adoption permitted. We have assessed the impact of this standard and do not believe that it will have a material impact on our consolidated financial statements or disclosures upon adoption.
	In May 2014, the FASB issued authoritative guidance amending the FASB Accounting Standards Codification and creating a new Topic 606, Revenue from Contracts with Customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP applicable to revenue transactions. This guidance provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The existing industry guidance will be eliminated when the new guidance becomes effective and annual disclosures will be substantially revised. The amendments in the new guidance are effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. Early application is not permitted. We intend to adopt the new standard effective January 1, 2017. This update provides for two transition methods to the new guidance: a full retrospective or a modified retrospective adoption. We are evaluating the transition methods and the anticipated impact the application of this guidance will have on our financial position, results of operations and cash flows.
	In July 2013, the FASB issued authoritative guidance which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS
	On November 25, 2014, we entered into a marketing, distribution, and license agreement with a medical device company for the right to market and distribute certain introducer shaft products. As of December 31, 2014, we had paid $624,800 in connection with this agreement. We are obligated to pay an additional €1.5 million if certain milestones set forth in the agreement are reached. We accounted for the transaction as an asset purchase. We recorded the amount paid on the closing date as a license agreement asset, which we intend to amortize over a period of 10 years.
	On August 8, 2014, we entered into a license agreement and a distribution agreement with a medical device company for the right to manufacture and sell certain percutaneous transluminal angioplasty balloon catheter products. As of December 31, 2014, we had paid $3.0 million and recorded an additional $1.0 million obligation to accrued liabilities in connection with these two agreements. We are obligated to pay an additional $3.0 million if certain milestones set forth in the license agreement are reached. We accounted for the transaction as an asset purchase. Of the purchase price paid as of December 31, 2014, $200,000 was allocated to a distribution agreement asset, which we are amortizing over a period of 3 years, and $3.8 million was allocated to a license agreement asset, which we intend to amortize over a period of 12 years.
	On July 15, 2014, we entered into a purchase agreement to acquire certain assets from a limited liability company. In connection with this agreement, we paid approximately $752,000. The primary assets acquired from this entity were manufacturing and export licenses. We accounted for the transaction as an asset purchase. We recorded the amount paid on the closing date as a license agreement asset, which we intend to amortize over a period of 10 years.
	On May 8, 2014, we purchased 737,628 shares of the common stock of G Medix, Inc., a Minnesota corporation ("G Medix"), for an aggregate price of approximately $1.8 million. Our purchase of the G Medix shares, which represents an ownership interest in G Medix of approximately 19%, has been accounted for at cost. We made a refundable advance to G Medix of $350,000 in 2013 that was credited against the final purchase amount, resulting in $1.45 million of cash purchase price paid to G Medix during 2014. G Medix develops catheter-based therapeutic devices.
	On December 20, 2013, we acquired a license to sell our Hepasphere products in China. We paid $700,000 to purchase the license, $350,000 of which was included in accrued liabilities at December 31, 2013. The purchase price was allocated to a license agreement for $700,000, which we are amortizing over four years.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement we executed with Datascope Corp. ("Datascope"), a Delaware corporation. The primary assets we acquired consist of the Safeguard® Pressure Assisted Device, which assists in obtaining and maintaining hemostasis after a femoral procedure, and the Air-Band™ Radial Compression Device, which is indicated to assist hemostasis of the radial artery puncture site while maintaining visibility. We accounted for this acquisition as a business combination. We made a payment of approximately $27.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Datascope products were approximately $1.6 million. It is not practical to separately report the earnings related to the Datascope acquisition, as we cannot split out sales costs related to Datascope products, principally because our sales representatives are selling multiple products (including Datascope products) in the cardiovascular business segment. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
	With respect to the Datascope assets, we are amortizing developed technology over 10 years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 10 years.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement with Radial Assist, LLC ("Radial Assist"), a Georgia limited liability company. The primary assets we acquired consist of the Rad Board, Rad BoardXtra, Rad Trac, and Rad Rest devices. The Rad Board is designed to provide a larger work space for physicians and an area for patients to rest their arms during radial procedures. The Rad Board Xtra is designed to work in conjunction with the Rad Board by extending the usable work space and allowing for a 90-degree perpendicular extension of the arm for physicians who prefer doing procedures at a 90-degree angle. The Rad Trac is also designed to be used with the Rad Board and facilitates placement and removal of the Rad Board with the patient still on the table. The Rad Rest is a disposable, single-use product designed to stabilize the arm by ergonomically supporting the elbow, forearm and wrist during radial procedures. We accounted for this acquisition as a business combination. We made a payment of approximately $2.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Radial Assist products were approximately $191,000. It is not practical to separately report the earnings related to the Radial Assist acquisition, as we cannot split out sales costs related to Radial Assist products, principally because our sales representatives are selling multiple products (including Radial Assist products) in the cardiovascular business segment. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500
	With respect to the Radial Assist assets, we are amortizing developed technology over 10 years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 10.07 years.
	In connection with our Datascope and Radial Assist acquisitions, we paid approximately $798,000 in long-term debt issuance costs to Wells Fargo Bank related to the amendment of our Credit Agreement (see Note 7). These costs consist primarily of loan origination fees that we are amortizing over the remaining contract term of our Credit Agreement, which matures December 19, 2017.
	On September 10, 2013, we entered into a license agreement with a medical device company for the exclusive rights to sell certain biocompatible gloves, instrument cleaners, and surgical wipes. We paid $250,000 for the use of the license. We are obligated to pay an additional $250,000 within 30 days of our first commercial sale of the product. The purchase price was allocated to a license agreement for $250,000, which we intend to amortize over 10 years.
	On December 19, 2012, we consummated the transactions contemplated by a Stock Purchase Agreement with Vital Signs, Inc., an affiliate of GE Healthcare (“Vital Signs”), as seller, and purchased all of the issued and outstanding shares of Thomas Medical Products, Inc. (“Thomas Medical”), a Pennsylvania corporation. The primary assets of Thomas Medical are the various patents, trademarks, and business related to introducers, hemostatic valves, and sheaths. Using the splittable hemostatic introducer sheath as an entry product, we intend to develop a portfolio of premium accessories for electrophysiology physicians. We accounted for this acquisition as a business combination. We made an initial payment of $167.0 million to Vital Signs in December 2012. We also accrued an additional $445,000 at December 31, 2012, related to a final payment made to Vital Signs in February 2013 for net working capital received in excess of the target net working capital specified. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. Our consolidated financial statements for the year ended December 31, 2012 include approximately $1.9 million and $51,000 of net sales and income before tax, respectively, related to the Thomas Medical acquisition. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Trade receivables	$	6,507
	Inventories	5,459
	Prepaid expenses	340
	Property and equipment	2,685
	Intangibles
	Developed technology	43,000
	Non-compete agreements	500
	Customer lists	5,000
	Trademarks	1,400
	Goodwill	102,407
	Total assets acquired	167,298
	Liabilities Assumed
	Trade payables	588
	Accrued expenses	1,094
	Total liabilities assumed	1,682
	Net assets acquired, net of cash acquired of $1,829	$	165,616
	During the year ended December 31, 2013, the goodwill related to the Thomas Medical acquisition was increased by approximately $381,000 due to an adjustment related to inventories.
	The gross amount of trade receivables we acquired in the Thomas Medical transaction was approximately $6.5 million, of which $34,000 was expected to be uncollectible. With respect to the Thomas Medical assets, we are amortizing developed technology over eight years, customer lists on an accelerated basis over 12 years, and non-compete agreements over three years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 8.55 years.
	In connection with our Thomas Medical acquisition, we paid approximately $3.7 million in long-term debt issuance costs to Wells Fargo Bank related to our Credit Agreement (see Note 7). These costs consist primarily of loan origination fees that we are amortizing over five years, which is the contract term of our Credit Agreement. We also incurred approximately $2.7 million of acquisition-related costs during the year ended December 31, 2012, which are included in selling, general and administrative expense in the accompanying consolidated statements of operations.
	On November 19, 2012, we entered into an Asset Purchase Agreement with Janin Group, Inc. (dba MediGroup) ("MediGroup"), an Illinois corporation, to purchase substantially all of the assets of MediGroup. The primary assets of MediGroup are the patented Flex-Neck® Peritoneal Dialysis Catheters and Y-TEC™ Peritoneal Dialysis Implantation Kits. We accounted for this acquisition as a business combination. We made an initial payment of approximately $4.0 million in November 2012. In addition, we are obligated to make contingent payments of up to $150,000 per year during 2013, 2014 and 2015. Furthermore, we are obligated to make contingent purchase price payments of $150,000 per year in 2016 through 2022 if net sales of Medigroup products increase at least 8% in each subsequent year. If net sales of MediGroup products have not increased by the percentage set forth in any year, our obligation to make these contingent payments shall cease. The acquisition-date fair value of the contingent consideration liability of approximately $403,000 was included as part of the purchase consideration. Acquisition-related costs during the year ended December 31, 2012, which are included in selling, general, and administrative expense in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2012, our net sales of MediGroup products were approximately $169,000. It is not practical to separately report the earnings related to the MediGroup acquisition, as we cannot split out sales costs related to MediGroup products, principally because our sales representatives are selling multiple products (including MediGroup products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	263
	Property and equipment	79
	Intangibles
	Developed technology	2,000
	Non-compete agreements	210
	Customer lists	110
	Trademarks	80
	Goodwill	1,697
	Total assets acquired	$	4,439
	With respect to the MediGroup assets, we are amortizing developed technology over eight years, customer lists on an accelerated basis over eight years, and non-compete agreements over seven years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 8.15 years.
	On August 27, 2012, we entered into a license agreement with a medical device company for the use of certain patents. We paid $750,000 for the use of the license. The purchase price was allocated to a license agreement for $750,000, which we are amortizing over three years.
	On August 21, 2012, we entered into a distribution and patent sublicense agreement with Catheter Connections, Inc. ("CathConn"), a Utah corporation, for the exclusive rights to sell certain disinfecting cap technologies. We paid CathConn $250,000 in August 2012 for the exclusive rights to distribute CathConn's MaleCap Solo technology in the field of interventional radiology and interventional cardiology. We can elect to pay an additional $250,000 for each of the exclusive rights to other aspects of CathConn's DualCap disinfecting cap technology. The purchase price was allocated to a distribution agreement for $250,000, which we intend to amortize over 10 years.
	On August 7, 2012, we purchased 422,594 special membership units, which represents an ownership interest of approximately 11.9%, of Blockade Medical LLC ("Blockade"), a Delaware limited liability company, for an aggregate price of approximately $1.0 million, which is accounted for at cost. Blockade develops, markets and sells catheter-based therapeutic devices.
On January 31, 2012, we consummated the transactions contemplated by an Asset Purchase Agreement with Ostial Solutions, LLC ("Ostial"), a Michigan limited liability company, to purchase substantially all of the assets of Ostial. The primary asset of Ostial is the patented Ostial PRO Stent Positioning System, which is designed to facilitate precise stent implantation in coronary and renal aorto-ostial lesions. We accounted for this acquisition as a business combination. We made an initial payment of $10.0 million to Ostial in January 2012 and an additional payment of $6.5 million to Ostial in August 2012. In addition, we are obligated to make contingent purchase price payments of up to $13.5 million based on a percentage of future sales of products utilizing the Ostial PRO Stent Positioning System. The acquisition-date fair value of this contingent consideration liability of $4.3 million was included as part of the purchase consideration and was determined using a discounted cash flow model based upon the expected timing and amount of these future contingent payments. Acquisition-related costs during the year ended December 31, 2012, which are included in selling, general, and administrative expense in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2012, our net sales of products utilizing the Ostial PRO Stent Positioning System were approximately $457,000. It is not practical to separately report the earnings related to the Ostial acquisition, as we cannot split out sales costs related to Ostial products, principally because our sales representatives are selling multiple products (including Ostial products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
Assets Acquired
Intangibles
Developed technology	$	10,500
Customer lists	600
Trademark	110
Non-compete agreements	10
Goodwill	9,580
Total assets acquired	$	20,800
With respect to the Ostial assets, we intend to amortize developed technology over 15 years, customer lists on an accelerated basis over eight years, and non-compete agreements over five years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 14.6 years.
The following table summarizes our unaudited consolidated results of operations for the years ended December 31, 2013 and 2012, as well as unaudited pro forma consolidated results of operations as though the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012 (in thousands, except per common share amounts):
		2013				2012
		As Reported		Pro Forma		As Reported		Pro Forma
Net sales		$	449,049	$	454,333	$	394,288	$	438,981
Net income		16,570		17,112		19,710		25,075
Earnings per common share:
Basic		$	0.39	$	0.4	$	0.47	$	0.59
Diluted		$	0.39	$	0.4	$	0.46	$	0.59
The unaudited pro forma information set forth above is for informational purposes only and includes adjustments related to the step-up of acquired inventories, amortization expense related to acquired intangible assets, and interest expense on long-term debt. The pro forma information should not be considered indicative of actual results that would have been achieved if the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012, or results that may be obtained in any future period. The pro forma consolidated results of operations do not include the Radial Assist acquisition, as we do not deem the pro forma effect of the transaction to be material.
On January 5, 2012, we entered into a Marketing and Distribution Agreement with Scion Cardio-Vascular, Inc. (“Scion”), a Florida corporation, wherein we purchased the exclusive, worldwide right to distribute the Clo-SurPLUS P.A.D.™ for $2.5 million. We made an initial payment of $1.5 million to Scion in January 2012. We made an additional payment of $1.0 million in May 2012 upon reaching a milestone set forth in the purchase agreement. The purchase price was allocated to a distribution agreement for $2.5 million, which we are amortizing over 12 years. As a result of entering into this agreement, we terminated several exclusive Scion sales distributor agreements where we had previously established direct sales relationships. In connection with the termination of these agreements, we agreed to purchase customer lists from the terminated distributors. The total purchase price of the customer lists was approximately $95,000 and was allocated to other intangible assets as of December 31, 2012. We are amortizing the customer lists on an accelerated basis over five years.
During the year ended December 31, 2012, we purchased several patents for the development of future products. A total charge of approximately $2.5 million related to these asset acquisitions has been recorded to acquired in-process research and development in the accompanying consolidated statements of income for the year ended December 31, 2012, as both technological feasibility of the underlying research and development projects had not yet been reached and such technology had no future alternative use as of the respective date of each asset acquisition.
The goodwill arising from the acquisitions discussed above consists largely of the synergies and economies of scale we hope to achieve from combining the acquired assets and operations with our historical operations (see Note 4). The goodwill recognized from these acquisitions is expected to be deductible for income tax purposes.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	Inventories at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014		2013
	Finished goods	$	50,000	$	43,364
	Work-in-process	7,680		6,222
	Raw materials	34,093		32,792
	Total	$	91,773	$	82,378

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS
	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013, are as follows (in thousands):
		2014			2013
	Goodwill balance at January 1	$	184,505		$	175,108
	Effect of foreign exchange	(41		)	$	—
	Adjustment related to previous acquisitions	—			381
	Additions as the result of acquisitions	—			9,016
	Goodwill balance at December 31	$	184,464		$	184,505
	As of December 31, 2014, we had recorded $8.3 million of accumulated goodwill impairment charges. All of the goodwill balance as of December 31, 2014 and 2013 related to our cardiovascular segment.
	Other intangible assets at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014
		Gross Carrying			Accumulated			Net Carrying
		Amount			Amortization			Amount
	Patents	$	10,199		$	(2,196	)	$	8,003
	Distribution agreements	5,376			(2,285		)	3,091
	License agreements	8,995			(1,823		)	7,172
	Trademarks	7,298			(2,079		)	5,219
	Covenants not to compete	1,029			(636		)	393
	Customer lists	20,452			(13,194		)	7,258
	Royalty agreements	267			(267		)	—
	Total	$	53,616		$	(22,480	)	$	31,136
		2013
		Gross Carrying			Accumulated			Net Carrying
		Amount			Amortization			Amount
	Patents	$	9,302		$	(2,374	)	$	6,928
	Distribution agreements	5,176			(1,780		)	3,396
	License agreements	3,783			(1,249		)	2,534
	Trademarks	7,622			(1,844		)	5,778
	Covenants not to compete	1,029			(399		)	630
	Customer lists	20,626			(10,957		)	9,669
	Royalty agreements	267			(267		)	—
	Total	$	47,805		$	(18,870	)	$	28,935
	Aggregate amortization expense for the years ended December 31, 2014, 2013 and 2012 was approximately $14.9 million, $14.2 million and $7.5 million, respectively.
	We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We compared the carrying value of the amortizing intangible assets acquired in our January 2012 acquisition of Ostial to the undiscounted cash flows expected to result from the asset group and determined that the carrying amount was not recoverable. We then determined the fair value of the amortizing assets related to the Ostial acquisition based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. Some of the factors that influenced our estimated cash flows were slower than anticipated sales growth in the products acquired from our Ostial acquisition and uncertainty about future sales growth. The excess of the carrying value compared to the fair value was recognized as an intangible asset impairment charge. During the third quarter of 2014 and 2013, we recorded impairment charges for Ostial of approximately $1.1 million and $8.1 million, respectively, which were offset by approximately $874,000 and $3.8 million, respectively, of fair value reductions to the related contingent consideration liability.
	Estimated amortization expense for the developed technology and other intangible assets for the next five years consists of the following as of December 31, 2014 (in thousands):
	Year Ending December 31
	2015	$	14,525
	2016	14,381
	2017	13,911
	2018	13,197
	2019	12,916

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	For the years ended December 31, 2014, 2013 and 2012, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):
		2014			2013			2012
	Domestic	$	16,961		$	5,435		$	15,958
	Foreign	14,611			14,404			11,660
	Total	$	31,572		$	19,839		$	27,618
	The components of the provision for income taxes for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014			2013			2012
	Current expense (benefit):
	Federal	$	1,316		$	(747	)	$	5,350
	State	768			333			1,014
	Foreign	2,644			2,324			995
	Total current expense	4,728			1,910			7,359
	Deferred expense (benefit):
	Federal	4,078			1,089			871
	State	(119		)	278			(343		)
	Foreign	(89		)	(8		)	21
	Total deferred expense	3,870			1,359			549
	Total income tax expense	$	8,598		$	3,269		$	7,908
	The difference between the income tax expense reported and amounts computed by applying the statutory federal rate of 35.0% to pretax income for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014			2013			2012
	Computed federal income tax expense at statutory rate of 35%	$	11,050		$	6,943		$	9,667
	State income taxes	438			397			436
	Tax credits	(888		)	(1,385		)	(779		)
	Production activity deduction	—			—			(388		)
	Foreign tax rate differential	(1,958		)	(2,374		)	(1,419		)
	Uncertain tax positions	(76		)	(520		)	(42		)
	Deferred compensation insurance assets	(81		)	(358		)	(155		)
	Other — including the effect of graduated rates	113			566			588
	Total income tax expense	$	8,598		$	3,269		$	7,908
	Deferred income tax assets and liabilities at December 31, 2014 and 2013, consisted of the following temporary differences and carry-forward items (in thousands):
		2014			2013
	Deferred income tax assets:
	Allowance for uncollectible accounts receivable	$	366		$	342
	Accrued compensation expense	5,492			5,001
	Inventory differences	2,401			2,317
	Net operating loss carryforwards	13,542			18,060
	Deferred revenue	87			280
	Stock-based compensation expense	2,479			2,704
	Uncertain tax positions	284			559
	Federal research and development credit carryforward	1,413			569
	Foreign Tax Credits	1,374			—
	Other	4,173			3,197
	Total deferred income tax assets	31,611			33,029
	Deferred income tax liabilities:
	Prepaid expenses	(708		)	(751		)
	Property and equipment	(23,298		)	(21,893		)
	Intangible assets	(4,853		)	(3,837		)
	Other	(1,150		)	(1,295		)
	Total deferred income tax liabilities	(30,009		)	(27,776		)
	Valuation allowance	(1,603		)	(1,363		)
	Net deferred income tax assets (liabilities)	$	(1	)	$	3,890
	Reported as:
	Deferred income tax assets - Current	$	6,375		$	5,638
	Deferred income tax assets - Long-term	9			800
	Deferred income tax liabilities - Current	—			—
	Deferred income tax liabilities - Long-term	(6,385		)	(2,548		)
	Net deferred income tax assets (liabilities)	$	(1	)	$	3,890
	The long-term deferred income tax balances are not netted as they represent deferred amounts applicable to different taxing jurisdictions. Deferred income tax balances reflect the temporary differences between the carrying amounts of assets and liabilities and their tax bases and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. The valuation allowance is primarily related to state credit carryforwards and capital losses for which we believe it is more likely than not that the deferred tax assets will not be realized. The valuation allowance increased by approximately $240,000, $138,000, and $864,000 during the years ended December 31, 2014, 2013 and 2012, respectively.
	We have not provided U.S. deferred income taxes or foreign withholding taxes on the undistributed earnings of certain foreign subsidiaries that are intended to be reinvested indefinitely in operations outside the United States. It is not practical to estimate the amount of additional taxes that might be payable on such undistributed earnings.
	As of December 31, 2014 and 2013, we had U.S federal net operating loss carryforwards of approximately $38.7 million and $52.2 million, respectively. These net operating loss carryforwards, which expire at various dates through 2030, are subject to an annual limitation under Internal Revenue Code Section 382. We anticipate that we will utilize the net operating loss carryforwards over the next 12 years. We utilized a total of approximately $13.5 million and $3.8 million in U.S. federal net operating loss carryforwards during the year ended December 31, 2014 and 2013, respectively.
	As of December 31, 2014 and 2013, we had non-U.S. net operating loss carryforwards of approximately $53,000 and $125,000, respectively, which have no expiration date. Non-U.S. net operating loss carryforwards utilized during 2014 and 2013 were not material.
	We are subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in determining our worldwide provision for income taxes and recording the related assets and liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. In our opinion, we have made adequate provisions for income taxes for all years subject to audit. We are no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for years before 2011. In foreign jurisdictions, we are no longer subject to income tax examinations for years before 2008.
	Although we believe our estimates are reasonable, the final outcomes of these matters may be different from those which we have reflected in our historical income tax provisions and accruals. Such differences could have a material effect on our income tax provision and operating results in the period in which we make such determination.
The total liability for unrecognized tax benefits at December 31, 2014, including interest and penalties, was approximately $1.9 million, of which approximately $1.6 million would favorably impact our effective tax rate if recognized. Approximately $563,000 of the total liability at December 31, 2014 was presented as a reduction to non-current deferred income tax assets on our consolidated balance sheet as of that date. The total liability for unrecognized tax benefits at December 31, 2013, including interest and penalties, was approximately $2.3 million, of which approximately $1.7 million would favorably impact our effective tax rate if recognized. Approximately $236,000 of the total liability at December 31, 2013 was presented as a reduction to non-current deferred income tax assets on our consolidated balance sheet as of that date. As of December 31, 2014 and 2013, we had accrued approximately $181,000 and $139,000 respectively, in total interest and penalties related to unrecognized tax benefits. We account for interest and penalties for unrecognized tax benefits as part of our income tax provision. During the year ended December 31, 2014, we added interest and penalties of approximately $42,000 to our liability for unrecognized tax benefits. During the years ended December 31, 2013 and 2012, we removed interest and penalties of approximately $22,000, and $215,000, respectively, from our liability for unrecognized tax benefits. The decrease in interest and penalties during 2012 was primarily related to an interest payment to the IRS in order to settle a withholding tax issue related to our acquisition of BioSphere. We anticipate the total liability for unrecognized tax benefits may be reduced, net of potential increases and decreases due to the expiration of statutes of limitation, by a range of approximately $400,000 to $800,000 within the next 12 months.
A reconciliation of the beginning and ending amount of liabilities associated with uncertain tax benefits for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
Tabular Roll-forward	2014			2013			2012
Unrecognized tax benefits, opening balance	$	2,129		$	2,776		$	3,113
Gross increases in tax positions taken in a prior year	142			107			83
Gross increases in tax positions taken in the current year	309			236			260
Lapse of applicable statute of limitations	(844		)	(990		)	(680		)
Unrecognized tax benefits, ending balance	$	1,736		$	2,129		$	2,776
The tabular roll-forward ending balance does not include interest and penalties related to unrecognized tax benefits.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	ACCRUED EXPENSES
	Accrued expenses at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014		2013
	Payroll taxes	$	1,931	$	1,816
	Payroll	4,086		3,474
	Bonuses	7,301		5,273
	Commissions	980		984
	Vacation	6,753		6,280
	Royalties	1,497		1,221
	Value-added tax	1,555		1,469
	Other accrued expenses	9,723		7,185
	Total	$	33,826	$	27,702

Revolving_Credit_Facility_and_

Revolving Credit Facility and Long-Term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Revolving Credit Facility and Long-Term Debt	REVOLVING CREDIT FACILITY AND LONG-TERM DEBT
	We entered into an Amended and Restated Credit Agreement, dated December 19, 2012, with the lenders who are or may become party thereto (collectively, the "Lenders") and Wells Fargo Bank, National Association ("Wells Fargo"), as administrative agent for the Lenders, which was amended on October 4, 2013 by a First Amendment to the Amended and Restated Credit Agreement by and among Merit, certain subsidiaries of Merit, the Lenders and Wells Fargo as administrative agent for the Lenders (as amended, the "Credit Agreement"). Pursuant to the terms of the Credit Agreement, the Lenders have agreed to make revolving credit loans up to an aggregate amount of $215 million. The Lenders also made a term loan in the amount of $100 million, repayable in quarterly installments in the amounts provided in the Credit Agreement until the maturity date of December 19, 2017, at which time the term and revolving credit loans, together with accrued interest thereon, will be due and payable. In addition, certain mandatory prepayments are required to be made upon the occurrence of certain events described in the Credit Agreement. Wells Fargo has agreed, upon satisfaction of certain conditions, to make swingline loans from time to time through the maturity date in amounts equal to the difference between the amounts actually loaned by the Lenders and the aggregate revolving credit commitment. The Credit Agreement is collateralized by substantially all of our assets. At any time prior to the maturity date, we may repay any amounts owing under all revolving credit loans, term loans, and all swingline loans in whole or in part, subject to certain minimum thresholds, without premium or penalty, other than breakage costs.
	The term loan and any revolving credit loans made under the Credit Agreement bear interest, at our election, at either (i) the base rate (described below) plus 0.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), (ii) the London Inter-Bank Offered Rate (“LIBOR”) Market Index Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), or (iii) the LIBOR Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, the term loan and revolving credit loans under the Credit Agreement bear interest, at our election, at either (x) the base rate plus 1.00%, (y) the LIBOR Market Index Rate, plus 2.00%, or (z) the LIBOR Rate plus 2.00%. Swingline loans bear interest at the LIBOR Market Index Rate plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, swingline loans bear interest at the LIBOR Market Index Rate plus 2.00%. Interest on each loan featuring the base rate or the LIBOR Market Index Rate is due and payable on the last business day of each calendar month; interest on each loan featuring the LIBOR Rate is due and payable on the last day of each interest period selected by us when selecting the LIBOR Rate as the benchmark for interest calculation. For purposes of the Credit Agreement, the base rate means the highest of (i) the prime rate (as announced by Wells Fargo), (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%. Our obligations under the Credit Agreement and all loans made thereunder are fully secured by a security interest in our assets pursuant to a separate collateral agreement entered into in conjunction with the Credit Agreement.
	The Credit Agreement contains customary covenants, representations and warranties and other terms customary for revolving credit loans of this nature. In this regard, the Credit Agreement requires us to not, among other things, (a) permit the Consolidated Total Leverage Ratio (as defined in the Credit Agreement) to be greater than 4.75 to 1 through the end of 2013, no more than 4.00 to 1 as of the fiscal quarter ending March 31, 2014, no more than 3.75 to 1 as of the fiscal quarter ending June 30, 2014, no more than 3.50 to 1 as of the fiscal quarter ending September 30, 2014, no more than 3.25 to 1 as of the fiscal quarter ending December 31, 2014, no more than 3.00 to 1 as of any fiscal quarter ending during 2015, no more than 2.75 to 1 as of any fiscal quarter ending during 2016, and no more than 2.50 to 1 as of any fiscal quarter ending thereafter; (b) for any period of four consecutive fiscal quarters, permit the ratio of Consolidated EBITDA (as defined in the Credit Agreement and subject to certain adjustments) to Consolidated Fixed Charges (as defined in the Credit Agreement) to be less than 1.75 to 1; (c) subject to certain adjustments, permit Consolidated Net Income (as defined in the Credit Agreement) for certain periods to be less than $0; or (d) subject to certain conditions and adjustments, permit the aggregate amount of all Facility Capital Expenditures (as defined in the Credit Agreement) in any fiscal year beginning in 2013 to exceed $30 million. Additionally, the Credit Agreement contains various negative covenants with which we must comply, including, but not limited to, limitations respecting: the incurrence of indebtedness, the creation of liens or pledges on our assets, mergers or similar combinations or liquidations, asset dispositions, the repurchase or redemption of equity interests or debt, the issuance of equity, the payment of dividends and certain distributions, the entry into related party transactions and other provisions customary in similar types of agreements. As of December 31, 2014, we were in compliance with all covenants set forth in the Credit Agreement.
	We had originally entered into an unsecured credit agreement, dated September 30, 2010, with certain lenders who were or became party thereto and Wells Fargo, as administrative agent for the lenders. Pursuant to the terms of that credit agreement, the lenders agreed to make revolving credit loans up to an aggregate amount of $175 million. Wells Fargo also agreed to make swingline loans from time to time through the maturity date of September 10, 2015 in amounts equal to the difference between the amount actually loaned by the lenders and the aggregate credit agreement. The unsecured credit agreement was amended and restated as of December 19, 2012, as the Credit Agreement.
	In summary, principal balances under our long-term debt as of December 31, 2014 and 2013, consisted of the following (in thousands):
		2014			2013
	Term loan	$	82,500		$	92,500
	Revolving credit loans	141,990			156,354
	Total long-term debt	224,490			248,854
	Less current portion	10,000			10,000
	Long-term portion	$	214,490		$	238,854
	Future minimum principal payments on our long-term debt as of December 31, 2014, are as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2015		$	10,000
	2016		10,000
	2017		204,490
	Total future minimum principal payments		$	224,490
	As of December 31, 2014, we had outstanding borrowings of approximately $224.5 million under the Credit Agreement, with available borrowings of approximately $27.5 million, based on the leverage ratio in the terms of the Credit Agreement. Our interest rate as of December 31, 2014 was a fixed rate of 2.98% on $140.0 million as a result of an interest rate swap (see Note 8), a variable floating rate of 2.17% on $84.3 million and a variable floating rate of 2.26% on approximately $0.2 million. Our interest rate as of December 31, 2013 was a fixed rate of 4.23% on $145.0 million as a result of an interest rate swap, variable floating rate of 3.42% on $101.5 million and a variable floating rate of 3.50% on approximately $2.4 million.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	DERIVATIVES
	General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of these risks by entering into derivative contracts. The derivatives we use are an interest rate swap and foreign currency forward contracts. We recognize derivatives as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether or not hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative programs are classified as operating activities in the accompanying consolidated statements of cash flows.
	We formally document, designate and assess the effectiveness of transactions that receive hedge accounting initially and on an ongoing basis. Changes in the fair value of derivatives that qualify for hedge accounting treatment are recorded, net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders’ equity in the accompanying consolidated balance sheets. For the ineffective portions of qualifying hedges, the change in fair value is recorded through earnings in the period of change. Changes in the fair value of derivatives not designated as cash flow hedges are recorded in earnings throughout the term of the derivative instrument.
	Interest Rate Swap. A portion of our debt bears interest at variable interest rates and therefore, we are subject to variability in the cash paid for interest expense. In order to mitigate a portion of this risk, we use a hedging strategy to reduce the variability of cash flows in the interest payments associated with a portion of the variable-rate debt outstanding under our Credit Agreement that is solely due to changes in the benchmark interest rate.
	On December 19, 2012, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $150 million with Wells Fargo to fix the one-month LIBOR rate at 0.98%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). The interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid, on a monthly basis. The notional amount of the interest rate swap is reduced quarterly by 50% of the minimum principal payment due under the terms of the Credit Agreement. The interest rate swap is scheduled to expire on December 19, 2017.
	At December 31, 2014 and 2013, our interest rate swap qualified as a cash flow hedge. The fair value of our interest rate swap at December 31, 2014 was an asset of approximately $573,000, which was offset by approximately $223,000 in deferred taxes. The fair value of our interest rate swap at December 31, 2013 was an asset of approximately $1.2 million, which was offset by approximately $468,000 in deferred taxes.
	During the years ended December 31, 2014, 2013 and 2012, the amount reclassified from accumulated other comprehensive income to earnings due to hedge effectiveness were included in interest expense in the accompanying consolidated statements of income and were not material.
	Foreign Currency Forward Contracts. On November 28, 2014, we forecasted a net exposure for December 31, 2014 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 899,000 Euros and 572,000 GBPs. In order to partially offset such risks at November 28, 2014, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 899,000 Euros and notional amount of 572,000 GBPs. On November 29, 2013, we forecasted a net exposure for December 31, 2013 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 494,000 Euros and 847,000 GBPs. In order to partially offset such risks at November 29, 2013, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 494,000 Euros and notional amount of 847,000 GBPs. We enter into similar transactions at various times during the year to partially offset exchange rate risks we bear throughout the year. These contracts are marked to market at each month-end. During the years ended December 31, 2014, 2013 and 2012, we recorded a net gain (loss) on all foreign currency transactions of approximately $36,000, $(202,000) and $(11,000), respectively, which is included in other income in the accompanying consolidated statements of income. The fair value of our open positions at December 31, 2014 and 2013 was not material.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES
	We are obligated under non-terminable operating leases for manufacturing facilities, finished good distribution, office space and equipment. Total rental expense on these operating leases and on our manufacturing and office building for the years ended December 31, 2014, 2013 and 2012, approximated $8.1 million, $5.5 million and $4.8 million, respectively.
	The future minimum lease payments for operating leases as of December 31, 2014, consisted of the following (in thousands):
	Years Ending	Operating
	December 31	Leases
	2015	$	8,870
	2016	8,465
	2017	7,438
	2018	7,030
	2019	7,038
	Thereafter	42,626
	Total minimum lease payments	$	81,467
	Sale-Leaseback. During the year ended December 31, 2014, we entered into sale and leaseback transactions to finance certain production equipment for $5.5 million. The lease agreements from the sale and leaseback transactions are accounted for as operating leases. Under the terms of the lease agreement, we will continue to operate and maintain the equipment. The lease term is seven years. During the fourth quarter of 2013, we entered into a sale and leaseback transaction with a third-party lessor for the sale and leaseback of our Pearland, Texas facility for $24.0 million. The lease agreement from this sale and leaseback transaction is accounted for as an operating lease. Under the terms of the lease agreement, we will continue to operate and maintain the building. The lease term is 19.8 years. Payments under the lease agreement are fixed. The lease agreement contains standard termination events, including termination upon a breach of our obligation to make rental payments and upon any other material breach of obligations under the lease, and standard maintenance and return condition provisions.
	Irish Government Development Agency Grants. As of December 31, 2014, we had entered into several grant agreements with the Irish Government Development Agency. We have recorded the grants related to research and development projects and costs of hiring and training employees as a reduction of operating expenses for the years ended December 31, 2014, 2013 and 2012 in the amounts of approximately $0, $1.2 million and $424,000, respectively. Grants related to the acquisition of property and equipment purchased in Ireland are amortized as a reduction to depreciation expense over lives corresponding to the depreciable lives of such property and equipment. The balance of deferred credits related to such grants as of December 31, 2014 and 2013, was approximately $2.9 million and $3.1 million, respectively. During the years ended December 31, 2014, 2013 and 2012, approximately $175,000, $139,000 and $174,000, respectively, of the deferred credit was amortized as a reduction of operating expenses.
	We have committed to repay the Irish government for grants received if we cease production in Ireland prior to the expiration of the grant liability period. The grant liability period is usually between five and eight years from the last claim made on a grant. As of December 31, 2014, the total amount of grants that could be subject to refund was approximately $4.4 million, and the remaining grant liability period was four years. Our management does not currently believe we will have to repay any of these grant monies, as we have no current intention of ceasing operations in Ireland.
	Litigation. In the ordinary course of business, we are involved in various claims and litigation matters. These claims and litigation matters may include actions involving product liability, intellectual property, contractual, and employment matters. We do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs for these matters such as outside counsel fees and expenses are charged to expense in the period incurred.

Earnings_Per_Common_Share_EPS

Earnings Per Common Share (EPS)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Earnings Per Common Share (EPS)	EARNINGS PER COMMON SHARE (EPS)
	The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Net		Shares	Per Share
		Income			Amount
	Year ended December 31, 2014:
	Basic EPS	$	22,974	43,143	$	0.53
	Effect of dilutive stock options and warrants			266
	Diluted EPS	$	22,974	43,409	$	0.53
	Year ended December 31, 2013:
	Basic EPS	$	16,570	42,607	$	0.39
	Effect of dilutive stock options and warrants			277
	Diluted EPS	$	16,570	42,884	$	0.39
	Year ended December 31, 2012:
	Basic EPS	$	19,710	42,176	$	0.47
	Effect of dilutive stock options and warrants			434
	Diluted EPS	$	19,710	42,610	$	0.46
	For the years ended December 31, 2014, 2013 and 2012, approximately 1,292,000, 1,823,000 and 1,588,000, respectively, of stock options were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

Employee_Stock_Purchase_Plan_S

Employee Stock Purchase Plan Stock Options and Warrants	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Purchase Plan Stock Options and Warrants	EMPLOYEE STOCK PURCHASE PLAN STOCK OPTIONS AND WARRANTS.
	Our stock-based compensation primarily consists of the following plans:
	2006 Long-Term Incentive Plan. In May 2006, our Board of Directors adopted and our shareholders approved, the Merit Medical Systems, Inc. 2006 Long-Term Incentive Plan (the “2006 Incentive Plan”). The 2006 Incentive Plan provides for the granting of stock options, stock appreciation rights, restricted stock, stock units (including restricted stock units) and performance awards. Options may be granted to directors, officers, outside consultants and key employees and may be granted upon such terms and such conditions as the Compensation Committee of our Board of Directors determines. Options will typically vest on an annual basis over a three to five year life (or one year if performance based) with contractual lives of seven to ten years. As of December 31, 2014, a total of approximately 447,000 shares remained available to be issued under the 2006 Incentive Plan.
	Employee Stock Purchase Plan. We have a qualified and a non-qualified Employee Stock Purchase Plan (“ESPP”), which has an expiration date of June 30, 2016. As of December 31, 2014, the total number of shares of Common Stock that remained available to be issued under our qualified plan was approximately 205,000 shares and 51,000 shares for our non-qualified plan. ESPP participants purchase shares on a quarterly basis at a price equal to 95% of the market price of the Common Stock at the end of the applicable offering period.
	Stock-Based Compensation Expense. The stock-based compensation expense before income tax expense for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cost of goods sold	$	198			$	145			$	245
	Research and development	69				87				119
	Selling, general, and administrative	1,193				1,235				1,553
	Stock-based compensation expense before taxes	$	1,460			$	1,467			$	1,917
	We recognize stock-based compensation expense (net of a forfeiture rate) for those awards which are expected to vest on a straight-line basis over the requisite service period. We estimate the forfeiture rate based on our historical experience and expectations about future forfeitures. As of December 31, 2014, the total remaining unrecognized compensation cost related to non-vested stock options, net of expected forfeitures, was approximately $4.9 million and is expected to be recognized over a weighted average period of 3.6 years.
	In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:
		2014				2013				2012
	Risk-free interest rate	1.53%	-	1.97%		0.65%	-	1.16%		0.54%	-	0.95%
	Expected option life	5	-	5.5 years		4.2	-	6.0 years		4.2	-	6.0 years
	Expected dividend yield	—%				—%				—%
	Expected price volatility	34.52%	-	36.90%		34.08%	-	41.67%		42.01%	-	44.56%
	The average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock option. We determine the expected term of the stock options using the historical exercise behavior of employees. The expected price volatility was determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option life and implied volatility based on recent trends of the daily historical volatility. For options with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period. Compensation expense is recognized immediately for options that are fully vested on the date of grant. During the years ended December 31, 2014, 2013 and 2012, approximately 666,000, 348,000 and 128,000 stock-based compensation grants were made, respectively, for a total fair value of approximately $2.8 million, $1.4 million and $677,000, net of estimated forfeitures, respectively.
	The table below presents information related to stock option activity for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		2014				2013				2012
	Total intrinsic value of stock options exercised	$	3,505			$	1,649			$	3,472
	Cash received from stock option exercises	7,697				3,281				3,325
	Excess tax benefit from the exercise of stock options	576				259				877
	Changes in stock options for the year ended December 31, 2014, consisted of the following (shares and intrinsic value in thousands):
		Number			Weighted Average				Remaining Contractual		Intrinsic
		of Shares			Exercise Price				Term (in years)		Value
	2014:00:00
	Beginning balance	3,008			$	12.14
	Granted	666			12.59
	Exercised	(878	)		11.03
	Forfeited/expired	(5	)		13.52
	Outstanding at December 31	2,791			12.6				3.7		$	13,210
	Exercisable	1,475			12.44				3.6		7,209
	Ending vested and expected to vest	2,710			12.6				1.9		12,833
	The weighted average grant-date fair value of options granted during the years ended December 31, 2014, 2013 and 2012 was $4.27, $5.31 and $5.28, respectively.
	The following table summarizes information about stock options outstanding at December 31, 2014 (shares in thousands):
								Options Outstanding							Options Exercisable
	Range of Exercise							Number Outstanding			Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
	$	9.71		-	$11.53			778			1.32		$	10.8	678	$	10.93
	$	12.06		-	$13.14			779			6.21		12.4		67	13.02
	$	13.16		-	$13.16			85			2.48		13.16		70	13.16
	$	13.75		-	$16.41			1,149			3.58		13.9		660	13.86
	$	9.71		-	$16.41			2,791							1,475

Segment_Reporting_and_Foreign_

Segment Reporting and Foreign Operations	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting and Foreign Operations	SEGMENT REPORTING AND FOREIGN OPERATIONS
	We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolization devices and the CRM/EP devices we acquired through our acquisition of Thomas Medical. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income (loss). Listed below are the sales by business segment for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		% Change			2014				% Change			2013		% Change		2012
	Cardiovascular
	Stand-alone devices	15	%		$	143,712			10	%		$	125,445	12	%	$	114,242
	Custom kits and procedure trays	7	%		111,076				10	%		103,700		3	%	94,586
	Inflation devices	10	%		72,538				(4	)%		66,182		2	%	68,979
	Catheters	17	%		87,550				16	%		75,131		17	%	64,878
	Embolization devices	31	%		43,855				(1	)%		33,395		8	%	33,870
	CRM/EP	17	%		32,975				1,359	%		28,271		—	%	1,938
	Total	14	%		491,706				14	%		432,124		9	%	378,493
	Endoscopy
	Endoscopy devices	6	%		17,983				7	%		16,925		31	%	15,795
	Total	14	%		$	509,689			14	%		$	449,049	10	%	$	394,288
	During the years ended December 31, 2014, 2013 and 2012, we had foreign sales of approximately $198.3 million, $165.8 million and $146.3 million, respectively, or approximately 39%, 37% and 37%, respectively, of total sales, primarily in China, Japan, Germany, France, the United Kingdom and Russia. Foreign sales are attributed based on location of the customer receiving the product.
	Our long-lived assets by geographic area at December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	United States	$	177,627			$	178,130			$	176,644
	Ireland	49,708				50,274				48,182
	Other foreign countries	16,836				14,866				9,977
	Total	$	244,171			$	243,270			$	234,803
	Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2014, 2013 and 2012, are as follows (in thousands):
		2014				2013				2012
	Revenues
	Cardiovascular	$	491,706			$	432,124			$	378,493
	Endoscopy	17,983				16,925				15,795
	Total revenues	509,689				449,049				394,288
	Operating expenses
	Cardiovascular	175,152				157,479				142,089
	Endoscopy	9,904				9,044				10,262
	Total operating expenses	185,056				166,523				152,351
	Operating income (loss)
	Cardiovascular	38,601				26,597				30,411
	Endoscopy	1,565				1,247				(770		)
	Total operating income	40,166				27,844				29,641
	Total other expense - net	(8,594		)		(8,005		)		(2,023		)
	Income tax expense	8,598				3,269				7,908
	Net income	$	22,974			$	16,570			$	19,710
	Total assets by business segment at December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	734,940			$	716,659			$	692,689
	Endoscopy	12,225				11,624				12,620
	Total	$	747,165			$	728,283			$	705,309
	Total depreciation and amortization by business segment for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	34,975			$	31,594			$	21,441
	Endoscopy	954				948				1,093
	Total	$	35,929			$	32,542			$	22,534
	Total capital expenditures by business segment for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	33,660			$	59,421			$	64,059
	Endoscopy	521				84				584
	Total	$	34,181			$	59,505			$	64,643

Royalty_Agreements

Royalty Agreements	12 Months Ended
	Dec. 31, 2014
Royalty Agreements [Abstract]
Royalty Agreements	ROYALTY AGREEMENTS
	During 2010, in connection with our acquisition of BioSphere, we entered into a running royalty agreement as part of a partnership between BioSphere and L’Assistance Publique-Hôpitaux de Paris, referred to as “AP-HP,” pursuant to which AP-HP has granted us the exclusive license to use two United States patents and their foreign counterparts that we jointly own with AP-HP relating to microspheres. We are required to pay to AP-HP a royalty on the commercial sale of any products that incorporate technology covered by the subject patents. We may sublicense these exclusive rights under the agreement only with the prior written consent of AP-HP, which consent cannot be unreasonably withheld. Under the terms of the royalty agreement, our exclusive license extends for both (i) the term of jointly owned U.S. and foreign counterpart patents and (ii) as long as the products and specialties implementing the patents are marketed. BioSphere filed patent applications which, if issued, will expire in approximately January 2031. The royalty rate in the agreement is 5.0% of net sales until the patents expire, and 2.5% of net sales thereafter as long as the product is sold. We paid or accrued approximately $1.5 million, $1.3 million and $1.4 million in royalty payments to AP-HP for the years ended December 31, 2014, 2013 and 2012, respectively.
	See Note 2 for a discussion of additional future royalty commitments related to acquisitions.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Employee Benefit Plans	EMPLOYEE BENEFIT PLANS
	We have a contributory 401(k) savings and profit sharing plan (the “Plan”) covering all U.S. full-time employees who are at least 18 years of age. The Plan has a 90-day minimum service requirement. We may contribute, at our discretion, matching contributions based on the employees’ compensation. Contributions we made to the Plan for the years ended December 31, 2014, 2013 and 2012, totaled approximately $1.8 million, $429,000 and $1.5 million, respectively. We have defined contribution plans covering some of our foreign employees. We contribute between 2% and 32% of the employee’s compensation for certain foreign non-management employees, and between 2% and 32% of the employee’s compensation for certain foreign management employees. Contributions made to these plans for the years ended December 31, 2014, 2013 and 2012, totaled approximately $912,000, $748,000 and $724,000, respectively.

Quarterly_Results_of_Operation

Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations (Unaudited)	QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)
	Quarterly data for the years ended December 31, 2014 and 2013 consisted of the following (in thousands, except per share amounts):
		Quarter Ended
		March 31			June 30		September 30		December 31
	2014
	Net sales	$	119,236		$	128,865	$	128,808	$	132,780
	Gross profit	52,043			55,624		57,421		60,134
	Income from operations	6,489			7,384		12,076		14,217
	Income tax expense	1,063			1,366		2,489		3,680
	Net income	2,823			3,716		7,764		8,671
	Basic earnings per common share	0.07			0.09		0.18		0.2
	Diluted earnings per common share	0.07			0.09		0.18		0.2
	2013
	Net sales	$	103,948		$	109,875	$	115,210	$	120,016
	Gross profit	42,993			46,985		51,030		53,359
	Income from operations	1,757			6,780		8,391		10,916
	Income tax expense (benefit)	(459		)	1,253		833		1,642
	Net income	671			3,752		5,607		6,540
	Basic earnings per common share	0.02			0.09		0.13		0.15
	Diluted earnings per common share	0.02			0.09		0.13		0.15
	Basic and diluted earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts may not equal the total computed for the year.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS
	Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of December 31, 2014 and 2013, consisted of the following (in thousands):
						Fair Value Measurements Using
			Total Fair			Quoted prices in			Significant other		Significant
			Value at			active markets			observable inputs		Unobservable inputs
	Description		31-Dec-14			(Level 1)			(Level 2)		(Level 3)
	Interest rate swap (1)		$	573		$	—		$	573	$	—
						Fair Value Measurements Using
			Total Fair			Quoted prices in			Significant other		Significant
			Value at			active markets			observable inputs		Unobservable inputs
	Description		31-Dec-13			(Level 1)			(Level 2)		(Level 3)
	Interest rate swap (1)		$	1,203		$	—		$	1,203	$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
	Certain of our business combinations involve the potential for the payment of future contingent consideration, generally based on a percentage of future product sales or upon attaining specified future revenue milestones. See Note 2 for further information regarding these acquisitions. The contingent consideration liability is re-measured at the estimated fair value at each reporting period with the change in fair value recognized within operating expenses in the accompanying consolidated statements of income. We measure the initial liability and re-measure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Changes in the fair value of our contingent consideration liability during the years ended December 31, 2014 and 2013, consisted of the following (in thousands):
		2014			2013
	Beginning balance	$	2,526		$	6,697
	Fair value adjustments recorded to income during the period	(572		)	(4,094		)
	Contingent payments made	(68		)	(77		)
	Ending balance	$	1,886		$	2,526
	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at December 31, 2014 and 2013 (amount in thousands):
	Contingent consideration liability		Fair value at December 31, 2014			Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	1,610		Discounted cash flow		Discount rate	1% - 14%
								Probability of milestone payment	90%
								Projected year of payments	2015-2028
	Other payments		$	276		Discounted cash flow		Discount rate	5%
								Probability of milestone payment	100%
								Projected year of payments	2015-2016
	Contingent consideration liability		Fair value at December 31, 2013			Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	2,282		Discounted cash flow		Discount rate	11% - 15%
								Probability of milestone payment	90%
								Projected year of payments	2014-2028
	Other payments		$	244		Discounted cash flow		Discount rate	5.40%
								Probability of milestone payment	100%
								Projected year of payments	2014-2016
	The contingent consideration liability is re-measured to fair value each reporting period using projected revenues, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases (decreases) in discount rates and the time to payment may result in lower (higher) fair value measurements. A decrease in the probability of any milestone payment may result in lower fair value measurements. An increase (decrease) in either the discount rate or the time to payment, in isolation, may result in a significantly lower (higher) fair value measurement.
	Our determination of the fair value of the contingent consideration liability could change in future periods based upon our ongoing evaluation of these significant unobservable inputs. We intend to record any such change in fair value to operating expenses in our consolidated statements of income. As of December 31, 2014, approximately $803,000 was included in other long-term obligations and $1.1 million was included in accrued expenses in our consolidated balance sheet. As of December 31, 2013, approximately $2.3 million was included in other long-term obligations and $274,000 was included in accrued expenses in our consolidated balance sheet. The cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) has been reflected as a cash outflow from financing activities in the accompanying consolidated statements of cash flows.
	During the years ended December 31, 2014, 2013 and 2012, we had losses of approximately $1.4 million, $8.2 million, and $55,000, respectively, related to the measurement of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition. Of the total loss in 2014, approximately $1.1 million related to the impairment of our intangible assets related to our Ostial acquisition (see Note 4) during the third quarter of 2014. The non-recurring fair value of the Ostial intangible asset as of September 30, 2014 was approximately $447,000 for developed technology. The fair value of these non-financial assets was measured using Level 3 inputs.
	During the quarter ended December 31, 2012, we recognized an impairment charge of approximately $2.4 million, which is included in other expense in the accompanying consolidated statement of income, related to an investment in a privately-held company accounted for at cost. As of December 31, 2012, there was no remaining cost included in our consolidated balance sheets related to this investment, which we deemed to be an appropriate valuation due to the financial position of the investee.
	The carrying amount of cash and cash equivalents, receivables, and trade payables approximates fair value because of the immediate, short-term maturity of these financial instruments. The carrying amount of long-term debt approximates fair value, as determined by borrowing rates estimated to be available to us for debt with similar terms and conditions. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 2 inputs, with the exception of cash and cash equivalents (Level 1).

Schedule_II_Valuation_and_qual

Schedule II - Valuation and qualifying accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and qualifying accounts	(2) Financial Statement Schedule.
	—                                   Schedule II - Valuation and qualifying accounts
	Years Ended December 31, 2014, 2013 and 2012
	(In thousands)
	Description	Balance at			Additions Charged to			Deduction (b)		Balance at
		Beginning of Year			Costs and Expenses (a)					End of Year
	ALLOWANCE FOR UNCOLLECTIBLE ACCOUNTS:
	2012	$	(464	)	$	(545	)	$	117	$	(892	)
	2013	(892		)	(376		)	428		(840		)
	2014	(840		)	(83		)	30		(893		)
	(a) We record a bad debt provision based upon historical experience and a review of individual customer balances.
	(b) When an individual customer balance becomes impaired and is deemed uncollectible, a deduction is made against the allowance for uncollectible accounts.
	Years Ended December 31, 2014, 2013 and 2012
	(In thousands)
	Description	Balance at			Additions Charged to			Deduction		Balance at
		Beginning of Year			Costs and Expenses (c)					End of Year
	TAX VALUATION ALLOWANCE:
	2012	$	(361	)	$	(864	)	$	—	$	(1,225	)
	2013	(1,225		)	(138		)	—		(1,363		)
	2014	(1,363		)	(240		)	—		(1,603		)
	(c) We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates in Preparing Financial Statements	Use of Estimates in Preparing Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation	Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.
Receivables	Receivables. The allowance for uncollectible accounts receivable is based on our historical bad debt experience and on management’s evaluation of our ability to collect individual outstanding balances.
Inventories	Inventories. We value our inventories at the lower of cost, determined on a first-in, first-out method, or market value.  Market value for raw materials is based on replacement costs. Inventory costs include material, labor and manufacturing overhead.  We review inventories on hand at least quarterly and record provisions for estimated excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. The regular and systematic inventory valuation reviews include a current assessment of future product demand, historical experience and product expiration.
Goodwill and Intangible Assets	Goodwill and Intangible Assets. We test goodwill balances as of July 1 for impairment on an annual basis during the third quarter, or whenever impairment indicators arise. We utilize several reporting units in evaluating goodwill for impairment. We assess the estimated fair value of reporting units using a combination of a market-based approach with a guideline public company method and a discounted cash flow method. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized in an amount equal to the excess of the carrying amount of the reporting unit goodwill over the implied fair value of that goodwill.
	We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	3	-	12 years
	License agreements and trademarks	3	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
Long-Lived Assets	Long-Lived Assets. We periodically review the carrying amount of our long-lived assets for impairment. An asset is considered impaired when estimated future cash flows are less than the carrying amount of the asset. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. There were no impairments of long-lived assets during the years ended December 31, 2014, 2013 and 2012
Property and Equipment	Property and Equipment. Property and equipment is stated at the historical cost of construction or purchase. Construction costs include interest costs capitalized during construction. Maintenance and repairs of property and equipment are charged to operations as incurred. Leasehold improvements are amortized over the lesser of the base term of the lease or estimated life of the leasehold improvements. Construction-in-process consists of new buildings and various production equipment being constructed internally and externally. Assets in construction-in-process will commence depreciating once the asset has been placed in service. Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years
Deferred Compensation	Deferred Compensation. We have a deferred compensation plan that permits certain management employees to defer a portion of their salary until the future. We established a Rabbi trust to finance obligations under the plan with corporate-owned variable life insurance contracts.
Other Assets	Other Assets. Other assets consist of our deferred compensation plan cash surrender value discussed above, unamortized debt issuance costs, two investments in privately-held companies accounted for at cost, a long-term income tax refund receivable, and deposits related to various leases.
Deferred Credits	Deferred Credits. Deferred credits consist of grant money received from the Irish government. Grant money is received for a percentage of expenditures on eligible property and equipment, specific research and development projects and costs of hiring and training employees. Amounts related to the acquisition of property and equipment are amortized as a reduction of depreciation expense over the lives of the corresponding property and equipment.
Revenue Recognition	Revenue Recognition. We sell our single-use disposable medical products through a direct sales force in the U.S., through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenues from these customers are recognized when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable and (iv) the ability to collect is reasonably assured. These criteria are generally satisfied at the time of shipment when risk of loss and title passes to the customer. We have certain written agreements with group purchasing organizations to sell our products to participating hospitals. These agreements have destination shipping terms which require us to defer the recognition of a sale until the product has arrived at the participating hospitals. We reserve for sales returns, including returns related to defective products (i.e. warranty liability), as a reduction in net sales, based on our historical experience. We also offer sales rebates and discounts to purchasing groups. These reserves are recorded as a reduction in net sales and are not considered material to our consolidated statements of income for the years ended December 31, 2014, 2013 and 2012. In addition, we invoice our customers for taxes assessed by governmental authorities such as sales tax and value added taxes. We present these taxes on a net basis.
Shipping and Handling Cost	Shipping and Handling. We bill our customers for shipping and handling charges, which are included in net sales for the applicable period, and the corresponding shipping and handling expense is reported in cost of sales.
Cost of Sales	Cost of Sales. We include product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, medical device excise tax, product royalty expense, developed technology amortization expense, production-related depreciation expense and product license agreement expense in cost of sales.
Research and Development	Research and Development. Research and development costs are expensed as incurred.
Income Taxes	Income Taxes. We utilize an asset and liability approach for financial accounting and reporting for income taxes. Deferred income taxes are provided for temporary differences in the basis of assets and liabilities as reported for financial statement and income tax purposes. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income for each full fiscal year.
Earnings per Common Share	Earnings per Common Share. Net income per common share is computed by both the basic method, which uses the weighted average number of our common shares outstanding, and the diluted method, which includes the dilutive common shares from stock options and warrants, as calculated using the treasury stock method.
Fair Value Measurements	Fair Value Measurements. The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market-based inputs or inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
Stock-Based Compensation	Stock-Based Compensation. We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation — Stock Compensation. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model.
Concentration of Credit Risk	Concentration of Credit Risk. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We provide credit, in the normal course of business, primarily to hospitals and independent third-party custom procedure tray manufacturers and distributors. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses.
Foreign Currency	Foreign Currency. The financial statements of our foreign subsidiaries are measured using local currencies as the functional currency, with the exception of Ireland which uses the U.S. Dollar as its functional currency. Assets and liabilities are translated into U.S. Dollars at year-end rates of exchange and results of operations are translated at average rates for the year. Gains and losses resulting from these translations are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Foreign currency transactions denominated in a currency other than the entity’s functional currency are included in determining net income for the period. Such foreign currency transaction gains and losses have not been significant for purposes of our financial reporting.
Derivatives	Derivatives. We use forward contracts to mitigate our exposure to volatility in foreign exchange rates, and we use an interest rate swap to hedge changes in the benchmark interest rate related to our Credit Agreement described in Note 7. All derivatives are recognized in the consolidated balance sheets at fair value. Classification of each hedging instrument is based upon whether the maturity of the instrument is less than or greater than 12 months. We do not purchase or hold derivative financial instruments for speculative or trading purposes (see Note 8).
Recently Issued Financial Accounting Standards	Recently Issued Financial Accounting Standards. In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2014-15, which requires management to assess, at each annual and interim reporting period, the entity's ability to continue as a going concern within one year after the date that the financial statements are issued and provide related disclosures. The guidance is effective for the year ended December 31, 2016, with early adoption permitted. We have assessed the impact of this standard and do not believe that it will have a material impact on our consolidated financial statements or disclosures upon adoption.
	In May 2014, the FASB issued authoritative guidance amending the FASB Accounting Standards Codification and creating a new Topic 606, Revenue from Contracts with Customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP applicable to revenue transactions. This guidance provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The existing industry guidance will be eliminated when the new guidance becomes effective and annual disclosures will be substantially revised. The amendments in the new guidance are effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. Early application is not permitted. We intend to adopt the new standard effective January 1, 2017. This update provides for two transition methods to the new guidance: a full retrospective or a modified retrospective adoption. We are evaluating the transition methods and the anticipated impact the application of this guidance will have on our financial position, results of operations and cash flows.
	In July 2013, the FASB issued authoritative guidance which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Intangible Assets	Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	3	-	12 years
	License agreements and trademarks	3	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
Property and Equipment	Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Thomas Medical Products, Inc
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Trade receivables	$	6,507
	Inventories	5,459
	Prepaid expenses	340
	Property and equipment	2,685
	Intangibles
	Developed technology	43,000
	Non-compete agreements	500
	Customer lists	5,000
	Trademarks	1,400
	Goodwill	102,407
	Total assets acquired	167,298
	Liabilities Assumed
	Trade payables	588
	Accrued expenses	1,094
	Total liabilities assumed	1,682
	Net assets acquired, net of cash acquired of $1,829	$	165,616
Business Acquisition, Pro Forma Information	The following table summarizes our unaudited consolidated results of operations for the years ended December 31, 2013 and 2012, as well as unaudited pro forma consolidated results of operations as though the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012 (in thousands, except per common share amounts):
			2013				2012
			As Reported		Pro Forma		As Reported		Pro Forma
	Net sales		$	449,049	$	454,333	$	394,288	$	438,981
	Net income		16,570		17,112		19,710		25,075
	Earnings per common share:
	Basic		$	0.39	$	0.4	$	0.47	$	0.59
	Diluted		$	0.39	$	0.4	$	0.46	$	0.59
MediGroup
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	263
	Property and equipment	79
	Intangibles
	Developed technology	2,000
	Non-compete agreements	210
	Customer lists	110
	Trademarks	80
	Goodwill	1,697
	Total assets acquired	$	4,439
Ostial Solutions, LLC
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Intangibles
	Developed technology	$	10,500
	Customer lists	600
	Trademark	110
	Non-compete agreements	10
	Goodwill	9,580
	Total assets acquired	$	20,800
Datascope
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
Radial Assist
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014		2013
	Finished goods	$	50,000	$	43,364
	Work-in-process	7,680		6,222
	Raw materials	34,093		32,792
	Total	$	91,773	$	82,378

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in carrying amount of goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013, are as follows (in thousands):
		2014			2013
	Goodwill balance at January 1	$	184,505		$	175,108
	Effect of foreign exchange	(41		)	$	—
	Adjustment related to previous acquisitions	—			381
	Additions as the result of acquisitions	—			9,016
	Goodwill balance at December 31	$	184,464		$	184,505
Other intangible assets	Other intangible assets at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014
		Gross Carrying			Accumulated			Net Carrying
		Amount			Amortization			Amount
	Patents	$	10,199		$	(2,196	)	$	8,003
	Distribution agreements	5,376			(2,285		)	3,091
	License agreements	8,995			(1,823		)	7,172
	Trademarks	7,298			(2,079		)	5,219
	Covenants not to compete	1,029			(636		)	393
	Customer lists	20,452			(13,194		)	7,258
	Royalty agreements	267			(267		)	—
	Total	$	53,616		$	(22,480	)	$	31,136
		2013
		Gross Carrying			Accumulated			Net Carrying
		Amount			Amortization			Amount
	Patents	$	9,302		$	(2,374	)	$	6,928
	Distribution agreements	5,176			(1,780		)	3,396
	License agreements	3,783			(1,249		)	2,534
	Trademarks	7,622			(1,844		)	5,778
	Covenants not to compete	1,029			(399		)	630
	Customer lists	20,626			(10,957		)	9,669
	Royalty agreements	267			(267		)	—
	Total	$	47,805		$	(18,870	)	$	28,935
Estimated amortization expense	Estimated amortization expense for the developed technology and other intangible assets for the next five years consists of the following as of December 31, 2014 (in thousands):
	Year Ending December 31
	2015	$	14,525
	2016	14,381
	2017	13,911
	2018	13,197
	2019	12,916

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	For the years ended December 31, 2014, 2013 and 2012, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):
		2014			2013			2012
	Domestic	$	16,961		$	5,435		$	15,958
	Foreign	14,611			14,404			11,660
	Total	$	31,572		$	19,839		$	27,618
Schedule of Components of Income Tax Expense (Benefit)	The components of the provision for income taxes for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014			2013			2012
	Current expense (benefit):
	Federal	$	1,316		$	(747	)	$	5,350
	State	768			333			1,014
	Foreign	2,644			2,324			995
	Total current expense	4,728			1,910			7,359
	Deferred expense (benefit):
	Federal	4,078			1,089			871
	State	(119		)	278			(343		)
	Foreign	(89		)	(8		)	21
	Total deferred expense	3,870			1,359			549
	Total income tax expense	$	8,598		$	3,269		$	7,908
Schedule of Effective Income Tax Rate Reconciliation	The difference between the income tax expense reported and amounts computed by applying the statutory federal rate of 35.0% to pretax income for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014			2013			2012
	Computed federal income tax expense at statutory rate of 35%	$	11,050		$	6,943		$	9,667
	State income taxes	438			397			436
	Tax credits	(888		)	(1,385		)	(779		)
	Production activity deduction	—			—			(388		)
	Foreign tax rate differential	(1,958		)	(2,374		)	(1,419		)
	Uncertain tax positions	(76		)	(520		)	(42		)
	Deferred compensation insurance assets	(81		)	(358		)	(155		)
	Other — including the effect of graduated rates	113			566			588
	Total income tax expense	$	8,598		$	3,269		$	7,908
Schedule of Deferred Tax Assets and Liabilities	Deferred income tax assets and liabilities at December 31, 2014 and 2013, consisted of the following temporary differences and carry-forward items (in thousands):
		2014			2013
	Deferred income tax assets:
	Allowance for uncollectible accounts receivable	$	366		$	342
	Accrued compensation expense	5,492			5,001
	Inventory differences	2,401			2,317
	Net operating loss carryforwards	13,542			18,060
	Deferred revenue	87			280
	Stock-based compensation expense	2,479			2,704
	Uncertain tax positions	284			559
	Federal research and development credit carryforward	1,413			569
	Foreign Tax Credits	1,374			—
	Other	4,173			3,197
	Total deferred income tax assets	31,611			33,029
	Deferred income tax liabilities:
	Prepaid expenses	(708		)	(751		)
	Property and equipment	(23,298		)	(21,893		)
	Intangible assets	(4,853		)	(3,837		)
	Other	(1,150		)	(1,295		)
	Total deferred income tax liabilities	(30,009		)	(27,776		)
	Valuation allowance	(1,603		)	(1,363		)
	Net deferred income tax assets (liabilities)	$	(1	)	$	3,890
	Reported as:
	Deferred income tax assets - Current	$	6,375		$	5,638
	Deferred income tax assets - Long-term	9			800
	Deferred income tax liabilities - Current	—			—
	Deferred income tax liabilities - Long-term	(6,385		)	(2,548		)
	Net deferred income tax assets (liabilities)	$	(1	)	$	3,890
Summary of Income Tax Contingencies	A reconciliation of the beginning and ending amount of liabilities associated with uncertain tax benefits for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
	Tabular Roll-forward	2014			2013			2012
	Unrecognized tax benefits, opening balance	$	2,129		$	2,776		$	3,113
	Gross increases in tax positions taken in a prior year	142			107			83
	Gross increases in tax positions taken in the current year	309			236			260
	Lapse of applicable statute of limitations	(844		)	(990		)	(680		)
	Unrecognized tax benefits, ending balance	$	1,736		$	2,129		$	2,776

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses at December 31, 2014 and 2013, consisted of the following (in thousands):
		2014		2013
	Payroll taxes	$	1,931	$	1,816
	Payroll	4,086		3,474
	Bonuses	7,301		5,273
	Commissions	980		984
	Vacation	6,753		6,280
	Royalties	1,497		1,221
	Value-added tax	1,555		1,469
	Other accrued expenses	9,723		7,185
	Total	$	33,826	$	27,702

Revolving_Credit_Facility_and_1

Revolving Credit Facility and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	In summary, principal balances under our long-term debt as of December 31, 2014 and 2013, consisted of the following (in thousands):
		2014			2013
	Term loan	$	82,500		$	92,500
	Revolving credit loans	141,990			156,354
	Total long-term debt	224,490			248,854
	Less current portion	10,000			10,000
	Long-term portion	$	214,490		$	238,854
Schedule of Maturities of Long-term Debt	Future minimum principal payments on our long-term debt as of December 31, 2014, are as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2015		$	10,000
	2016		10,000
	2017		204,490
	Total future minimum principal payments		$	224,490

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum lease payments for operating leases as of December 31, 2014, consisted of the following (in thousands):
	Years Ending	Operating
	December 31	Leases
	2015	$	8,870
	2016	8,465
	2017	7,438
	2018	7,030
	2019	7,038
	Thereafter	42,626
	Total minimum lease payments	$	81,467

Earnings_Per_Common_Share_EPS_

Earnings Per Common Share (EPS) (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Net		Shares	Per Share
		Income			Amount
	Year ended December 31, 2014:
	Basic EPS	$	22,974	43,143	$	0.53
	Effect of dilutive stock options and warrants			266
	Diluted EPS	$	22,974	43,409	$	0.53
	Year ended December 31, 2013:
	Basic EPS	$	16,570	42,607	$	0.39
	Effect of dilutive stock options and warrants			277
	Diluted EPS	$	16,570	42,884	$	0.39
	Year ended December 31, 2012:
	Basic EPS	$	19,710	42,176	$	0.47
	Effect of dilutive stock options and warrants			434
	Diluted EPS	$	19,710	42,610	$	0.46

Employee_Stock_Purchase_Plan_S1

Employee Stock Purchase Plan Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The stock-based compensation expense before income tax expense for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cost of goods sold	$	198			$	145			$	245
	Research and development	69				87				119
	Selling, general, and administrative	1,193				1,235				1,553
	Stock-based compensation expense before taxes	$	1,460			$	1,467			$	1,917
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:
		2014				2013				2012
	Risk-free interest rate	1.53%	-	1.97%		0.65%	-	1.16%		0.54%	-	0.95%
	Expected option life	5	-	5.5 years		4.2	-	6.0 years		4.2	-	6.0 years
	Expected dividend yield	—%				—%				—%
	Expected price volatility	34.52%	-	36.90%		34.08%	-	41.67%		42.01%	-	44.56%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable	The table below presents information related to stock option activity for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		2014				2013				2012
	Total intrinsic value of stock options exercised	$	3,505			$	1,649			$	3,472
	Cash received from stock option exercises	7,697				3,281				3,325
	Excess tax benefit from the exercise of stock options	576				259				877
Schedule of Share-based Compensation, Stock Options, Activity	Changes in stock options for the year ended December 31, 2014, consisted of the following (shares and intrinsic value in thousands):
		Number			Weighted Average				Remaining Contractual		Intrinsic
		of Shares			Exercise Price				Term (in years)		Value
	2014:00:00
	Beginning balance	3,008			$	12.14
	Granted	666			12.59
	Exercised	(878	)		11.03
	Forfeited/expired	(5	)		13.52
	Outstanding at December 31	2,791			12.6				3.7		$	13,210
	Exercisable	1,475			12.44				3.6		7,209
	Ending vested and expected to vest	2,710			12.6				1.9		12,833
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	The following table summarizes information about stock options outstanding at December 31, 2014 (shares in thousands):
								Options Outstanding							Options Exercisable
	Range of Exercise							Number Outstanding			Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
	$	9.71		-	$11.53			778			1.32		$	10.8	678	$	10.93
	$	12.06		-	$13.14			779			6.21		12.4		67	13.02
	$	13.16		-	$13.16			85			2.48		13.16		70	13.16
	$	13.75		-	$16.41			1,149			3.58		13.9		660	13.86
	$	9.71		-	$16.41			2,791							1,475

Segment_Reporting_and_Foreign_1

Segment Reporting and Foreign Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenue from External Customers by Products and Services	Listed below are the sales by business segment for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		% Change			2014				% Change			2013		% Change		2012
	Cardiovascular
	Stand-alone devices	15	%		$	143,712			10	%		$	125,445	12	%	$	114,242
	Custom kits and procedure trays	7	%		111,076				10	%		103,700		3	%	94,586
	Inflation devices	10	%		72,538				(4	)%		66,182		2	%	68,979
	Catheters	17	%		87,550				16	%		75,131		17	%	64,878
	Embolization devices	31	%		43,855				(1	)%		33,395		8	%	33,870
	CRM/EP	17	%		32,975				1,359	%		28,271		—	%	1,938
	Total	14	%		491,706				14	%		432,124		9	%	378,493
	Endoscopy
	Endoscopy devices	6	%		17,983				7	%		16,925		31	%	15,795
	Total	14	%		$	509,689			14	%		$	449,049	10	%	$	394,288
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Our long-lived assets by geographic area at December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	United States	$	177,627			$	178,130			$	176,644
	Ireland	49,708				50,274				48,182
	Other foreign countries	16,836				14,866				9,977
	Total	$	244,171			$	243,270			$	234,803
Schedule of Segment Reporting Information, by Segment	Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2014, 2013 and 2012, are as follows (in thousands):
		2014				2013				2012
	Revenues
	Cardiovascular	$	491,706			$	432,124			$	378,493
	Endoscopy	17,983				16,925				15,795
	Total revenues	509,689				449,049				394,288
	Operating expenses
	Cardiovascular	175,152				157,479				142,089
	Endoscopy	9,904				9,044				10,262
	Total operating expenses	185,056				166,523				152,351
	Operating income (loss)
	Cardiovascular	38,601				26,597				30,411
	Endoscopy	1,565				1,247				(770		)
	Total operating income	40,166				27,844				29,641
	Total other expense - net	(8,594		)		(8,005		)		(2,023		)
	Income tax expense	8,598				3,269				7,908
	Net income	$	22,974			$	16,570			$	19,710
Reconciliation of Assets from Segment to Consolidated	Total assets by business segment at December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	734,940			$	716,659			$	692,689
	Endoscopy	12,225				11,624				12,620
	Total	$	747,165			$	728,283			$	705,309
Segment Depreciation And Amortization	Total depreciation and amortization by business segment for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	34,975			$	31,594			$	21,441
	Endoscopy	954				948				1,093
	Total	$	35,929			$	32,542			$	22,534
Segment Capital Expenditures	Total capital expenditures by business segment for the years ended December 31, 2014, 2013 and 2012, consisted of the following (in thousands):
		2014				2013				2012
	Cardiovascular	$	33,660			$	59,421			$	64,059
	Endoscopy	521				84				584
	Total	$	34,181			$	59,505			$	64,643

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Quarterly data for the years ended December 31, 2014 and 2013 consisted of the following (in thousands, except per share amounts):
		Quarter Ended
		March 31			June 30		September 30		December 31
	2014
	Net sales	$	119,236		$	128,865	$	128,808	$	132,780
	Gross profit	52,043			55,624		57,421		60,134
	Income from operations	6,489			7,384		12,076		14,217
	Income tax expense	1,063			1,366		2,489		3,680
	Net income	2,823			3,716		7,764		8,671
	Basic earnings per common share	0.07			0.09		0.18		0.2
	Diluted earnings per common share	0.07			0.09		0.18		0.2
	2013
	Net sales	$	103,948		$	109,875	$	115,210	$	120,016
	Gross profit	42,993			46,985		51,030		53,359
	Income from operations	1,757			6,780		8,391		10,916
	Income tax expense (benefit)	(459		)	1,253		833		1,642
	Net income	671			3,752		5,607		6,540
	Basic earnings per common share	0.02			0.09		0.13		0.15
	Diluted earnings per common share	0.02			0.09		0.13		0.15

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of December 31, 2014 and 2013, consisted of the following (in thousands):
						Fair Value Measurements Using
			Total Fair			Quoted prices in			Significant other		Significant
			Value at			active markets			observable inputs		Unobservable inputs
	Description		31-Dec-14			(Level 1)			(Level 2)		(Level 3)
	Interest rate swap (1)		$	573		$	—		$	573	$	—
						Fair Value Measurements Using
			Total Fair			Quoted prices in			Significant other		Significant
			Value at			active markets			observable inputs		Unobservable inputs
	Description		31-Dec-13			(Level 1)			(Level 2)		(Level 3)
	Interest rate swap (1)		$	1,203		$	—		$	1,203	$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	Changes in the fair value of our contingent consideration liability during the years ended December 31, 2014 and 2013, consisted of the following (in thousands):
		2014			2013
	Beginning balance	$	2,526		$	6,697
	Fair value adjustments recorded to income during the period	(572		)	(4,094		)
	Contingent payments made	(68		)	(77		)
	Ending balance	$	1,886		$	2,526
Fair Value Inputs, Liabilities, Quantitative Information	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at December 31, 2014 and 2013 (amount in thousands):
	Contingent consideration liability		Fair value at December 31, 2014			Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	1,610		Discounted cash flow		Discount rate	1% - 14%
								Probability of milestone payment	90%
								Projected year of payments	2015-2028
	Other payments		$	276		Discounted cash flow		Discount rate	5%
								Probability of milestone payment	100%
								Projected year of payments	2015-2016
	Contingent consideration liability		Fair value at December 31, 2013			Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	2,282		Discounted cash flow		Discount rate	11% - 15%
								Probability of milestone payment	90%
								Projected year of payments	2014-2028
	Other payments		$	244		Discounted cash flow		Discount rate	5.40%
								Probability of milestone payment	100%
								Projected year of payments	2014-2016

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Organization (Details)	12 Months Ended
	Dec. 31, 2014
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Intangible Assets (Details)	0 Months Ended							12 Months Ended
	Aug. 08, 2014	Aug. 21, 2012	Jan. 05, 2012	Nov. 25, 2014	Jul. 15, 2014	Dec. 20, 2013	Sep. 10, 2013	Dec. 31, 2014
Distribution agreements
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years	10 years	12 years
License agreements and trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years			10 years	10 years	4 years	10 years
Patents
Finite-Lived Intangible Assets [Line Items]
Useful life								17 years
Royalty agreements
Finite-Lived Intangible Assets [Line Items]
Useful life								5 years
Minimum | Customer lists
Finite-Lived Intangible Assets [Line Items]
Useful life								2 years
Minimum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Useful life								5 years
Minimum | Distribution agreements
Finite-Lived Intangible Assets [Line Items]
Useful life								3 years
Minimum | License agreements and trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life								3 years
Minimum | Covenant not to compete
Finite-Lived Intangible Assets [Line Items]
Useful life								3 years
Maximum | Customer lists
Finite-Lived Intangible Assets [Line Items]
Useful life								15 years
Maximum | Developed technology
Finite-Lived Intangible Assets [Line Items]
Useful life								15 years
Maximum | Distribution agreements
Finite-Lived Intangible Assets [Line Items]
Useful life								12 years
Maximum | License agreements and trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life								15 years
Maximum | Covenant not to compete
Finite-Lived Intangible Assets [Line Items]
Useful life								10 years

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Property and Equipment (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation	$21	$18.40	$15
Building
Property, Plant and Equipment [Line Items]
Useful life	40 years
Minimum | Manufacturing equipment
Property, Plant and Equipment [Line Items]
Useful life	4 years
Minimum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life	3 years
Minimum | Land improvements
Property, Plant and Equipment [Line Items]
Useful life	10 years
Minimum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life	4 years
Maximum | Manufacturing equipment
Property, Plant and Equipment [Line Items]
Useful life	20 years
Maximum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life	20 years
Maximum | Land improvements
Property, Plant and Equipment [Line Items]
Useful life	20 years
Maximum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life	25 years

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies - Deferred Compensation (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash Surrender Value of Life Insurance	$9,000,000	$7,800,000
Deferred Compensation Liability, Classified, Noncurrent	$8,635,000	$7,833,000

Organization_and_Summary_of_Si7

Organization and Summary of Significant Accounting Policies - Other Assets (Details)	Dec. 31, 2014
	investment
Accounting Policies [Abstract]
Other Assets, Deferred Compensation Plan, Number of Investments, Cost Method	2

Organization_and_Summary_of_Si8

Organization and Summary of Significant Accounting Policies - Stock Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Allocated Share-based Compensation Expense	$1,460	$1,467	$1,917

Organization_and_Summary_of_Si9

Organization and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Concentration Risk, Percentage	3.00%	3.00%	4.00%

Recovered_Sheet1

Organization and Summary of Significant Accounting Policies - Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated other comprehensive income (loss), interest rate swaps, net of tax	$350	$735
Accumulated other comprehensive income (loss), interest rate swap, tax benefit	-223	-468
Accumulated other comprehensive income (loss) related to foreign currency translation, net of tax	-2,800	208
Accumulated other comprehensive income (loss), foreign currency translation, tax benefit	$202	$12

Acquisitions_Purchase_Price_Al

Acquisitions - Purchase Price Allocation (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 04, 2013	Jan. 31, 2012	Nov. 19, 2012	Dec. 19, 2012
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$184,464	$184,505	$175,108
Radial Assist
Business Acquisition [Line Items]
Inventories				16
Goodwill				904
Total assets acquired				2,500
Datascope
Business Acquisition [Line Items]
Inventories				478
Goodwill				8,112
Total assets acquired				27,500
Ostial Solutions, LLC
Business Acquisition [Line Items]
Goodwill					9,580
Total assets acquired					20,800
MediGroup
Business Acquisition [Line Items]
Inventories						263
Property and equipment						79
Goodwill						1,697
Total assets acquired						4,439
Thomas Medical Products, Inc
Business Acquisition [Line Items]
Trade receivables							6,507
Inventories							5,459
Prepaid expenses							340
Property and equipment							2,685
Goodwill							102,407
Total assets acquired							167,298
Accounts payable							588
Accrued expenses							1,094
Total liabilities assumed							1,682
Net assets acquired, net of cash acquired							165,616
Cash acquired							1,829
Developed technology | Radial Assist
Business Acquisition [Line Items]
Intangibles				1,520
Developed technology | Datascope
Business Acquisition [Line Items]
Intangibles				18,200
Developed technology | Ostial Solutions, LLC
Business Acquisition [Line Items]
Intangibles					10,500
Developed technology | MediGroup
Business Acquisition [Line Items]
Intangibles						2,000
Developed technology | Thomas Medical Products, Inc
Business Acquisition [Line Items]
Intangibles							43,000
Customer lists | Radial Assist
Business Acquisition [Line Items]
Intangibles				20
Customer lists | Datascope
Business Acquisition [Line Items]
Intangibles				390
Customer lists | Ostial Solutions, LLC
Business Acquisition [Line Items]
Intangibles					600
Customer lists | MediGroup
Business Acquisition [Line Items]
Intangibles						110
Customer lists | Thomas Medical Products, Inc
Business Acquisition [Line Items]
Intangibles							5,000
Trademarks | Radial Assist
Business Acquisition [Line Items]
Intangibles				40
Trademarks | Datascope
Business Acquisition [Line Items]
Intangibles				320
Trademarks | Ostial Solutions, LLC
Business Acquisition [Line Items]
Intangibles					110
Trademarks | MediGroup
Business Acquisition [Line Items]
Intangibles						80
Trademarks | Thomas Medical Products, Inc
Business Acquisition [Line Items]
Intangibles							1,400
Non-compete agreements | Ostial Solutions, LLC
Business Acquisition [Line Items]
Intangibles					10
Non-compete agreements | MediGroup
Business Acquisition [Line Items]
Intangibles						210
Non-compete agreements | Thomas Medical Products, Inc
Business Acquisition [Line Items]
Intangibles							$500

Acquisitions_Pro_Forma_Consoli

Acquisitions - Pro Forma Consolidated Results (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]
Revenues	$132,780	$128,808	$128,865	$119,236	$120,016	$115,210	$109,875	$103,948	$509,689	$449,049	$394,288
Sales, Pro Forma										454,333	438,981
Net income									22,974	16,570	19,710
Net income, Pro Forma										$17,112	$25,075
EARNINGS PER COMMON SHARE:
Earnings per common share: basic (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.47
Earnings per common share: basic, Pro Forma (in dollars per share)										$0.40	$0.59
Earnings per common share: diluted (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.46
Earnings per common share: diluted, Pro Forma (in dollars per share)										$0.40	$0.59

Acquisitions_Narrative_Details

Acquisitions - Narrative (Details)

0 Months Ended

1 Months Ended

5 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

Jul. 15, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 25, 2014

Aug. 08, 2014

Aug. 07, 2012

Aug. 07, 2012

Oct. 04, 2013

Dec. 19, 2012

Aug. 07, 2012

Nov. 25, 2014

Aug. 08, 2014

Jul. 15, 2014

Dec. 20, 2013

Dec. 20, 2013

Sep. 10, 2013

Dec. 31, 2014

Dec. 31, 2013

Sep. 10, 2013

Aug. 08, 2014

Aug. 21, 2012

Jan. 05, 2012

31-May-12

Jan. 31, 2012

Dec. 31, 2014

Aug. 08, 2014

Dec. 31, 2013

Aug. 21, 2012

Jan. 05, 2012

Dec. 31, 2014

Aug. 08, 2014

Dec. 31, 2013

Jan. 05, 2012

Dec. 31, 2014

Dec. 31, 2013

Jan. 05, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Aug. 27, 2012

Aug. 27, 2012

8-May-14

Dec. 31, 2014

Dec. 31, 2013

8-May-14

Oct. 04, 2013

Dec. 31, 2013

Oct. 04, 2013

Oct. 04, 2013

Oct. 04, 2013

Oct. 04, 2013

Dec. 31, 2013

Oct. 04, 2013

Oct. 04, 2013

Oct. 04, 2013

Dec. 31, 2012

Dec. 19, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 19, 2012

Dec. 19, 2012

Dec. 19, 2012

Dec. 19, 2012

Dec. 19, 2012

Nov. 19, 2012

Dec. 31, 2012

Nov. 19, 2012

Nov. 19, 2012

Nov. 19, 2012

Nov. 19, 2012

Nov. 19, 2012

Jan. 31, 2012

Aug. 31, 2012

Jan. 31, 2012

Dec. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

Blockade Medical LLC

Blockade Medical LLC

Wells Fargo Credit Agreement

Wells Fargo Credit Agreement

Special Membership Units

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Developed technology

Developed technology

Developed technology

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Trademarks

Trademarks

Non-compete agreements

Non-compete agreements

License Agreement Terms

License Agreement Terms

GMedix

GMedix

GMedix

GMedix

Datascope

Datascope

Datascope

Datascope

Datascope

Radial Assist

Radial Assist

Radial Assist

Radial Assist

Radial Assist

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

MediGroup

MediGroup

MediGroup

MediGroup

MediGroup

MediGroup

MediGroup

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

USD ($)

USD ($)

USD ($)

Blockade Medical LLC

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Developed technology

Customer Lists

Trademarks

USD ($)

USD ($)

Developed technology

Customer Lists

Trademarks

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Developed technology

Customer Lists

Trademarks

Non-compete agreements

USD ($)

USD ($)

USD ($)

Developed technology

Customer Lists

Trademarks

Non-compete agreements

USD ($)

USD ($)

USD ($)

USD ($)

Developed technology

Customer Lists

Trademarks

Non-compete agreements

Business Acquisition [Line Items]

Payments to acquire intangible assets

$625,000

$3,000,000

$1,714,000

$1,617,000

$1,460,000

$700,000

$250,000

$250,000

$1,000,000

$1,500,000

$750,000

Liabilities incurred in agreement

1,000,000

1,000,000

1,000,000

Contingent consideration, liability

1,500,000

3,000,000

403,000

4,300,000

Useful life

10 years

12 years

10 years

4 years

10 years

3 years

10 years

12 years

3 years

10 years

6 years

15 years

10 years

6 years

15 years

8 years

12 years

15 years

3 years

8 years

8 years

15 years

7 years

15 years

8 years

15 years

5 years

Intangible assets

200,000

3,800,000

Payments to acquire investments

752,000

1,000,000

1,800,000

Cost method investments, shares acquired

422,594

737,628

Cost method investments, ownership percentage

11.90%

19.00%

Payments to acquire businesses, net of cash acquired

5,927,000

31,600,000

192,762,000

1,450,000

350,000

Accrued liabilities

33,826,000

33,826,000

33,826,000

27,702,000

350,000

250,000

Finite-lived intangible assets, gross

700,000

8,995,000

3,783,000

250,000

5,376,000

5,176,000

20,452,000

20,626,000

7,298,000

7,622,000

1,029,000

1,029,000

Payments to acquire businesses

27,500,000

2,500,000

167,000,000

4,000,000

6,500,000

10,000,000

Income before tax

1,600,000

191,000

51,000

Weighted average useful life

5 years

10 years

10 years 0 months 27 days

8 years 6 months 18 days

8 years 1 month 24 days

14 years 7 months 6 days

Long-term debt issuance costs

0

798,000

3,706,000

798,000

3,700,000

Due date in relation to first commercial sale

30 days

Liabilities incurred

445,000

Net sales

1,900,000

169,000

457,000

Goodwill, period increase (decrease)

381,000

Acquired receivables

6,500,000

Estimated uncollectible trade receivables acquired

34,000

Acquisition-related costs

2,700,000

Contingent consideration, payment, 2013

150,000

Contingent consideration, payment, 2014

150,000

Contingent consideration, payment, 2015

150,000

Contingent consideration, potential payment, 2016

150,000

Contingent consideration, potential payment, 2017

150,000

Contingent consideration, potential payment, 2018

150,000

Contingent consideration, potential payment, 2019

150,000

Contingent consideration, potential payment, 2020

150,000

Contingent consideration, potential payment, 2021

150,000

Contingent consideration, potential payment, 2022

150,000

Potential payment, annual increase in net sales, minimum percent

8.00%

Intangible assets purchased

7,172,000

2,534,000

3,091,000

3,396,000

250,000

2,500,000

79,172,000

91,052,000

7,258,000

9,669,000

95,000

5,219,000

5,778,000

393,000

630,000

750,000

Contingent consideration, potential payment

250,000

13,500,000

Acquired in-process research and development

$0

$0

$2,450,000

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Finished goods	$50,000	$43,364
Work-in-process	7,680	6,222
Raw materials	34,093	32,792
Total	$91,773	$82,378

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Goodwill (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill balance at January 1	$184,505	$175,108
Effect of foreign exchange	-41	0
Adjustment related to previous acquisitions	0	381
Additions as the result of acquisitions	0	9,016
Goodwill balance at December 31	$184,464	$184,505

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Other Intangible Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 21, 2012	Jan. 05, 2012	Dec. 20, 2013	Sep. 10, 2013
In Thousands, unless otherwise specified
Other
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$53,616	$47,805
Accumulated Amortization	-22,480	-18,870
Net Carrying Amount	31,136	28,935
Patents
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	10,199	9,302
Accumulated Amortization	-2,196	-2,374
Net Carrying Amount	8,003	6,928
Distribution agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	5,376	5,176
Accumulated Amortization	-2,285	-1,780
Net Carrying Amount	3,091	3,396	250	2,500
License agreements and trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	8,995	3,783			700	250
Accumulated Amortization	-1,823	-1,249
Net Carrying Amount	7,172	2,534
Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	7,298	7,622
Accumulated Amortization	-2,079	-1,844
Net Carrying Amount	5,219	5,778
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,029	1,029
Accumulated Amortization	-636	-399
Net Carrying Amount	393	630
Customer lists
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	20,452	20,626
Accumulated Amortization	-13,194	-10,957
Net Carrying Amount	7,258	9,669		95
Royalty agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	267	267
Accumulated Amortization	-267	-267
Net Carrying Amount	$0	$0

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Future Amortization Expense (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$14,525
2016	14,381
2017	13,911
2018	13,197
2019	$12,916

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Narrative (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]
Accumulated impairment loss	$8,300,000
Aggregate amortization expense	14,900,000	14,200,000	7,500,000
Intangible asset impairment charges	1,102,000	8,089,000	0
Ostial Solutions, LLC
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges				1,100,000	8,100,000
Contingent consideration benefit				$874,000	$3,800,000

Income_Taxes_Domestic_and_Fore

Income Taxes - Domestic and Foreign (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Domestic									$16,961	$5,435	$15,958
Foreign									14,611	14,404	11,660
INCOME BEFORE INCOME TAXES	$14,217	$12,076	$7,384	$6,489	$10,916	$8,391	$6,780	$1,757	$31,572	$19,839	$27,618

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense (Benefit) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current expense (benefit):
Federal									$1,316	($747)	$5,350
State									768	333	1,014
Foreign									2,644	2,324	995
Total current expense									4,728	1,910	7,359
Deferred expense (benefit):
Federal									4,078	1,089	871
State									-119	278	-343
Foreign									-89	-8	21
Total deferred expense									3,870	1,359	549
Total income tax expense	$3,680	$2,489	$1,366	$1,063	$1,642	$833	$1,253	($459)	$8,598	$3,269	$7,908

Income_Taxes_Effective_Income_

Income Taxes - Effective Income Tax Rate Reconciliation (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Computed federal income tax expense at statutory rate of 35%									$11,050	$6,943	$9,667
State income taxes									438	397	436
Tax credits									-888	-1,385	-779
Production activity deduction									0	0	-388
Foreign tax rate differential									-1,958	-2,374	-1,419
Uncertain tax positions									-76	-520	-42
Deferred compensation insurance assets									-81	-358	-155
Other — including the effect of graduated rates									113	566	588
Total income tax expense	$3,680	$2,489	$1,366	$1,063	$1,642	$833	$1,253	($459)	$8,598	$3,269	$7,908

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred income tax assets:
Allowance for uncollectible accounts receivable	$366	$342
Accrued compensation expense	5,492	5,001
Inventory differences	2,401	2,317
Net operating loss carryforwards	13,542	18,060
Deferred revenue	87	280
Stock-based compensation expense	2,479	2,704
Uncertain tax positions	284	559
Federal research and development credit carryforward	1,413	569
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	1,374	0
Other	4,173	3,197
Total deferred income tax assets	31,611	33,029
Deferred income tax liabilities:
Prepaid expenses	-708	-751
Property and equipment	-23,298	-21,893
Intangible assets	-4,853	-3,837
Other	-1,150	-1,295
Total deferred income tax liabilities	-30,009	-27,776
Valuation allowance	-1,603	-1,363
Net deferred income tax assets (liabilities)	-1	3,890
Reported as:
Deferred income tax assets - Current	6,375	5,638
Deferred income tax assets - Long-term	9	800
Deferred income tax liabilities - Long-term	($6,385)	($2,548)

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Tax Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, opening balance	$2,129	$2,776	$3,113
Gross increases in tax positions taken in a prior year	142	107	83
Gross increases in tax positions taken in the current year	309	236	260
Lapse of applicable statute of limitations	-844	-990	-680
Unrecognized tax benefits, ending balance	$1,736	$2,129	$2,776

Income_Taxes_Narrative_Details

Income Taxes - Narrative (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Valuation Allowance, Deferred Tax Asset, Change in Amount	$240,000	$138,000	$864,000
U.S federal net operating loss carryforwards	38,700,000	52,200,000
Net Operating Loss Carryforwards Utilization	12 years
Net Operating Loss Carryforwards Used In The Current Period	13,500,000	3,800,000
non-U.S. net operating loss carryforwards	53,000	125,000
Unrecognized Tax Benefits Gross Including Interest and Penalties		1,900,000	2,300,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		1,600,000	1,700,000
Gross increases in tax positions taken in the current year	309,000	236,000	260,000
Deferred Tax Asset, Reduction in Valuation Allowance, Noncurrent	563,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	181,000	139,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	42,000	22,000	215,000
Estimated change in unrecognized tax benefit in next twelve months, lower bound	400,000
Estimated change in unrecognized tax benefit in next twelve months, upper bound	$800,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	35.00%

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Payroll taxes	$1,931	$1,816
Payroll	4,086	3,474
Bonuses	7,301	5,273
Commissions	980	984
Vacation	6,753	6,280
Royalties	1,497	1,221
Value-added tax	1,555	1,469
Other accrued expenses	9,723	7,185
Total	$33,826	$27,702

Revolving_Credit_Facility_and_2

Revolving Credit Facility and Long-Term Debt - Narrative (Details) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 19, 2012	Dec. 31, 2013	Oct. 04, 2013	Sep. 30, 2010
	quarter
Credit Agreement
Line of Credit Facility [Line Items]
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Current Quarter, Maximum	4.75
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter One, Maximum	4
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Two, Maximum	3.75
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Three, Maximum	3.5
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Four, Maximum	3.25
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Two, Maximum	3
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Three, Maximum	2.75
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Four, Maximum	2.5
Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Number of Consecutive Quarters	4
Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Minimum	1.75
Line of Credit Facility, Covenant Terms, Consolidated Net Income, Maximum	$0
Line of Credit Facility, Covenant Terms, Facility Capital Expenditures, Next Twelve Months, Maximum	30,000,000
Line of Credit Facility, Amount Outstanding	224,500,000
Line of Credit Facility, Remaining Borrowing Capacity	27,500,000
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	2.98%		4.23%
Long-term Debt, Percentage Bearing Fixed Interest, Amount	140,000,000		145,000,000
Base Rate | Credit Agreement
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.25%	1.00%
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum	2.25
London Interbank Offered Rate (LIBOR) Market Index Rate | Credit Agreement
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%	2.00%
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum	2.25
London Interbank Offered Rate (LIBOR) | Credit Agreement
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%	2.00%
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum	2.25
Debt Instrument, Basis Spread on Base Rate	0.01
Federal Funds Rate | Credit Agreement
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Base Rate	0.005
Variable Rate 1 | Credit Agreement
Line of Credit Facility [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	2.17%		3.42%
Long-term Debt, Percentage Bearing Variable Interest, Amount	84,300,000		101,500,000
Variable Rate 2 | Credit Agreement
Line of Credit Facility [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	2.26%		3.50%
Long-term Debt, Percentage Bearing Variable Interest, Amount	174,000		2,400,000
Revolving Credit Facility | Credit Agreement
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				215,000,000
Revolving Credit Facility | Wells Fargo
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					175,000,000
Term Loan | Credit Agreement
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		100,000,000
Bridge Loan | Base Rate | Credit Agreement
Line of Credit Facility [Line Items]
Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum	2.25
Bridge Loan | London Interbank Offered Rate (LIBOR) Market Index Rate | Credit Agreement
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%	2.00%

Revolving_Credit_Facility_and_3

Revolving Credit Facility and Long-Term Debt - Principal Balances under Long-term Debt (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Line of Credit Facility [Line Items]
Total long-term debt	$224,490	$248,854
Less current portion	10,000	10,000
Long-term portion	214,490	238,854
Term Loan
Line of Credit Facility [Line Items]
Total long-term debt	82,500	92,500
Revolving Credit Facility
Line of Credit Facility [Line Items]
Total long-term debt	$141,990	$156,354

Revolving_Credit_Facility_and_4

Revolving Credit Facility and Long-Term Debt - Future Minimum Payments on Long-term Debt (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$10,000
2016	10,000
2017	204,490
Total long-term debt	$224,490	$248,854

Derivatives_Interest_Rate_Swap

Derivatives - Interest Rate Swap (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 19, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional Amount of Interest Rate Cash Flow Hedge Derivatives			$150,000,000
Derivative, Fixed Interest Rate			0.98%
Quarterly reduction of notional amount	50.00%
Interest rate asset	573,000	1,200,000
Accumulated other comprehensive income (loss), interest rate swap, tax benefit	$223,000	$468,000

Derivatives_Foreign_Currency_F

Derivatives - Foreign Currency Forward Contracts (Details)	12 Months Ended			0 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 29, 2013	Nov. 30, 2012	Nov. 28, 2014	Nov. 29, 2013	Nov. 30, 2012	Nov. 28, 2014
	USD ($)	USD ($)	USD ($)	30 Day Forward Contract EURO	30 Day Forward Contract EURO	30 Day Forward Contract EURO	30 Day Forward Contract GBP	30 Day Forward Contract GBP	30 Day Forward Contract GBP
				EUR (€)		EUR (€)	GBP (£)		GBP (£)
Derivatives, Fair Value [Line Items]
Forward Contract Term				30 days	30 days		30 days	30 days
Derivative, Notional Amount				€ 494		€ 899	£ 847		£ 572
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	$36	($202)	($11)

Commitments_and_Contingencies_1

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$8,870
2016	8,465
2017	7,438
2018	7,030
2019	7,038
Thereafter	42,626
Total minimum lease payments	$81,467

Commitments_and_Contingencies_2

Commitments and Contingencies (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Commitments [Line Items]
Operating Leases, Rent Expense		$8,100,000	$5,500,000	$4,800,000
Proceeds from sale-leaseback transactions	24,000,000	5,521,000	24,000,000	0
Lessee Leasing Arrangements, Operating Leases, Term of Contract	19 years 10 months	7 years
Irish Grants Related to Research and Development, Training and Hiring		0	1,200,000	424,000
Deferred Credits and Other Liabilities	3,100,000	2,900,000	3,100,000
Irish Grants Related to Purchased Property Plant and Equipment		175,000	139,000	174,000
Refundable Irish Grants if Operations Cease		$4,400,000
Remaining grant liability period		4 years
Minimum
Other Commitments [Line Items]
Grant liability period		5 years
Maximum
Other Commitments [Line Items]
Grant liability period		8 years

Earnings_Per_Common_Share_EPS_1

Earnings Per Common Share (EPS) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share, Basic and Diluted [Abstract]
Net Income, Basic EPS									$22,974	$16,570	$19,710
Shares, Basic EPS									43,143	42,607	42,176
Basic (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.47
Effect of dilutive stock options and warrants									266	277	434
Net Income, Diluted EPS									$22,974	$16,570	$19,710
Shares, Diluted EPS									43,409	42,884	42,610
Diluted (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.46
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									1,292	1,823	1,588

Employee_Stock_Purchase_Plan_S2

Employee Stock Purchase Plan Stock Options and Warrants - Long Term Incentive Plans (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
2006 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	447
Employee Stock Purchase Plan Qualified
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	205
Share Based Compensation Arrangement Employee Stock Purchase Plan Percentage of Market Price Purchase Date	95.00%
Employee Stock Purchase Plan Non Qualified
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	51
Stock Options | 2006 Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Stock Option Contractual Life	7 years
Stock Options | 2006 Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years
Stock Option Contractual Life	10 years
Performance Shares | 2006 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Employee_Stock_Purchase_Plan_S3

Employee Stock Purchase Plan Stock Options and Warrants - Allocation of Recognized Period Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$1,460,000	$1,467,000	$1,917,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	4,900,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	3 years 6 months 20 days
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	198,000	145,000	245,000
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	69,000	87,000	119,000
Selling, general, and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$1,193,000	$1,235,000	$1,553,000

Employee_Stock_Purchase_Plan_S4

Employee Stock Purchase Plan Stock Options and Warrants - Fair Value Calculation Assumptions (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.53%	0.65%	0.54%
Risk-free interest rate, maximum	1.97%	1.16%	0.95%
Expected dividend yield	0.00%	0.00%	0.00%
Expected price volatility, minimum	34.52%	34.08%	42.01%
Expected price volatility, maximum	36.90%	41.67%	44.56%
Stock-based compensation grants	666	348	128
Stock-based compensation grants, total fair value	$2,800	$1,400	$677
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	5 years 0 months 0 days	4 years 2 months 12 days	4 years 2 months 12 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	5 years 6 months	6 years	6 years

Employee_Stock_Purchase_Plan_S5

Employee Stock Purchase Plan Stock Options and Warrants - Stock Option Activity (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Total intrinsic value of stock options exercised	$3,505	$1,649	$3,472
Cash received from stock option exercises	7,697	3,281	3,325
Excess tax benefit from the exercise of stock options	576	259	877
Number of Shares
Beginning balance (in shares)	3,008
Granted (in shares)	666
Exercised (in shares)	-878
Forfeited/expired (in shares)	-5
Outstanding at December 31 (in shares)	2,791	3,008
Exercisable (in shares)	1,475
Ending vested and expected to vest (in shares)	2,710
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$12.60	$12.14
Granted (in dollars per share)	$12.59
Exercised (in shares)	$11.03
Forfeited/expired (in shares)	$13.52
Outstanding at December 31 (in dollars per share)	$12.60	$12.14
Exercisable (in dollars per share)	$12.44
Ending vested and expected to vest (in dollars per share)	$12.60
Outstanding, Remaining Contractual Term	3 years 7 months 25 days
Outstanding, Intrinsic Value	13,210
Exercisable, Remaining Contractual Term	3 years 6 months 31 days
Exercisable, Intrinsic Value	7,209
Ending vested and expected to vest, Remaining Contractual Term	1 year 11 months 5 days
Ending vested and expected to vest, Intrinsic Value	$12,833
Weighted average grant-date fair value of options granted	$4.27	$5.31	$5.28

Employee_Stock_Purchase_Plan_S6

Employee Stock Purchase Plan Stock Options and Warrants - Options Outstanding (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise	$9.71
Range of Exercise	$16.41
Number Outstanding	2,791
Number Exercisable	1,475
$9.71 - $11.53
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise	$9.71
Range of Exercise	$11.53
Number Outstanding	778
Weighted Average Remaining Contractual Life (in years)	1 year 3 months 25 days
Weighted Average Exercise Price	$10.80
Number Exercisable	678
Weighted Average Exercise Price	$10.93
$12.06 - $13.14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise	$12.06
Range of Exercise	$13.14
Number Outstanding	779
Weighted Average Remaining Contractual Life (in years)	6 years 2 months 15 days
Weighted Average Exercise Price	$12.40
Number Exercisable	67
Weighted Average Exercise Price	$13.02
$13.16 - $13.16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise	$13.16
Range of Exercise	$13.16
Number Outstanding	85
Weighted Average Remaining Contractual Life (in years)	2 years 5 months 22 days
Weighted Average Exercise Price	$13.16
Number Exercisable	70
Weighted Average Exercise Price	$13.16
$13.75 - $16.41
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise	$13.75
Range of Exercise	$16.41
Number Outstanding	1,149
Weighted Average Remaining Contractual Life (in years)	3 years 6 months 30 days
Weighted Average Exercise Price	$13.90
Number Exercisable	660
Weighted Average Exercise Price	$13.86

Segment_Reporting_and_Foreign_2

Segment Reporting and Foreign Operations - Narrative (Details)	12 Months Ended
	Dec. 31, 2014
	segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment_Reporting_and_Foreign_3

Segment Reporting and Foreign Operations - Sales by Business Segment (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue from External Customer [Line Items]
Revenues	$132,780	$128,808	$128,865	$119,236	$120,016	$115,210	$109,875	$103,948	$509,689	$449,049	$394,288
% Change	14.00%				14.00%				14.00%	14.00%	10.00%
Cardiovascular Segment
Revenue from External Customer [Line Items]
Revenues									491,706	432,124	378,493
% Change	14.00%				14.00%				14.00%	14.00%	9.00%
Cardiovascular Segment | Stand Alone Devices
Revenue from External Customer [Line Items]
Revenues									143,712	125,445	114,242
% Change	15.00%				10.00%				15.00%	10.00%	12.00%
Cardiovascular Segment | Custom Kit And Procedures Trays
Revenue from External Customer [Line Items]
Revenues									111,076	103,700	94,586
% Change	7.00%				10.00%				7.00%	10.00%	3.00%
Cardiovascular Segment | Inflation Devices
Revenue from External Customer [Line Items]
Revenues									72,538	66,182	68,979
% Change	10.00%				-4.00%				10.00%	-4.00%	2.00%
Cardiovascular Segment | Catheters
Revenue from External Customer [Line Items]
Revenues									87,550	75,131	64,878
% Change	17.00%				16.00%				17.00%	16.00%	17.00%
Cardiovascular Segment | Embolization Devices
Revenue from External Customer [Line Items]
Revenues									43,855	33,395	33,870
% Change	31.00%				-1.00%				31.00%	-1.00%	8.00%
Cardiovascular Segment | Electrophysiology
Revenue from External Customer [Line Items]
Revenues									32,975	28,271	1,938
% Change	17.00%				1359.00%				17.00%	1359.00%	0.00%
Endoscopy Segment
Revenue from External Customer [Line Items]
Revenues									17,983	16,925	15,795
Endoscopy Segment | Endoscopy Devices
Revenue from External Customer [Line Items]
Revenues									$17,983	$16,925	$15,795
% Change	6.00%				7.00%				6.00%	7.00%	31.00%

Segment_Reporting_and_Foreign_4

Segment Reporting and Foreign Operations - Foreign Sales (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Foreign Sales Percent of Total Sales	39.00%	37.00%	37.00%
Foreign Sales
Segment Reporting Information [Line Items]
Revenue, Net	$198.30	$165.80	$146.30

Segment_Reporting_and_Foreign_5

Segment Reporting and Foreign Operations - Long-lived Assets by Geographic Area (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$244,171	$243,270	$234,803
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	177,627	178,130	176,644
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	49,708	50,274	48,182
Other Foreign Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$16,836	$14,866	$9,977

Segment_Reporting_and_Foreign_6

Segment Reporting and Foreign Operations - Operating Income (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$132,780	$128,808	$128,865	$119,236	$120,016	$115,210	$109,875	$103,948	$509,689	$449,049	$394,288
Operating expenses									185,056	166,523	152,351
Operating income (loss)									40,166	27,844	29,641
Total other expense - net									-8,594	-8,005	-2,023
Income tax expense	3,680	2,489	1,366	1,063	1,642	833	1,253	-459	8,598	3,269	7,908
NET INCOME									22,974	16,570	19,710
Cardiovascular Segment
Segment Reporting Information [Line Items]
Revenues									491,706	432,124	378,493
Operating expenses									175,152	157,479	142,089
Operating income (loss)									38,601	26,597	30,411
Endoscopy Segment
Segment Reporting Information [Line Items]
Revenues									17,983	16,925	15,795
Operating expenses									9,904	9,044	10,262
Operating income (loss)									$1,565	$1,247	($770)

Segment_Reporting_and_Foreign_7

Segment Reporting and Foreign Operations - Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$747,165	$728,283	$705,309
Depreciation and amortization	35,929	32,542	22,534
Capital expenditures	34,181	59,505	64,643
Cardiovascular Segment
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	734,940	716,659	692,689
Depreciation and amortization	34,975	31,594	21,441
Capital expenditures	33,660	59,421	64,059
Endoscopy Segment
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	12,225	11,624	12,620
Depreciation and amortization	954	948	1,093
Capital expenditures	$521	$84	$584

Royalty_Agreements_Details

Royalty Agreements (Details) (BioSphere APHP Royalty, USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
BioSphere APHP Royalty
Royalty Agreements [Line Items]
Current Royalty Rate	5.00%
Future Royalty Rate	2.50%
Royalty Expense	$1.50	$1.30	$1.40

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Minimum Years Of Age	18 years
Minimum Service Requirement	90 days
Defined Contribution Plan, Cost Recognized	$1,800	$429	$1,500
Defined Contribution Plan Percentage Minimum Foreign Employees	2.00%
Defined Contribution Plan Percentage Maximum Foreign Employees	32.00%
Defined Contribution Plan Percentage Minimum Foreign Management	2.00%
Defined Contribution Plan Foreign, Cost Recognized	$912	$748	$724

Quarterly_Results_of_Operation2

Quarterly Results of Operations (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net sales	$132,780	$128,808	$128,865	$119,236	$120,016	$115,210	$109,875	$103,948	$509,689	$449,049	$394,288
Gross profit	60,134	57,421	55,624	52,043	53,359	51,030	46,985	42,993	225,222	194,367	181,992
Income from operations	14,217	12,076	7,384	6,489	10,916	8,391	6,780	1,757	31,572	19,839	27,618
Income tax expense	3,680	2,489	1,366	1,063	1,642	833	1,253	-459	8,598	3,269	7,908
Net income	$8,671	$7,764	$3,716	$2,823	$6,540	$5,607	$3,752	$671
Basic (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.47
Diluted (in dollars per share)	$0.20	$0.18	$0.09	$0.07	$0.15	$0.13	$0.09	$0.02	$0.53	$0.39	$0.46

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets and (Liabilities) Carried at Fair Value (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	$573		$1,200
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	0	[1]	0	[1]
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	573	[1]	1,203	[1]
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	0	[1]	0	[1]
Estimate of Fair Value, Fair Value Disclosure | Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap	$573	[1]	$1,203	[1]
[1]	The fair value of the interest rate swap is determined based on forward yield curves.

Fair_Value_Measurements_Liabil

Fair Value Measurements - Liability Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (Contingent Consideration, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$2,526	$6,697
Fair value adjustments recorded to income during the period	-572	-4,094
Contingent payments made	-68	-77
Ending balance	$1,886	$2,526

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Inputs, Liabilities, Quantitative Information (Details) (Contingent Consideration, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration liability	1,886	2,526	$6,697
Revenue-based Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration liability	1,610	2,282
Revenue-based Payments | Income Approach Valuation Technique | Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestone payment	90.00%	90.00%
Revenue-based Payments | Minimum | Income Approach Valuation Technique | Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	1.00%	11.00%
Revenue-based Payments | Maximum | Income Approach Valuation Technique | Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	14.00%	15.00%
Other Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration liability	276	244
Other Payments | Income Approach Valuation Technique | Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	5.00%	5.40%
Probability of milestone payment	100.00%	100.00%

Fair_Value_Measurements_Narrat

Fair Value Measurements - Narrative (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Asset Impairment Charges		$1,400,000	$8,200,000	$55,000
Goodwill impairment charge		1,100,000
Impairment of cost-method investment	2,368,000	0	0	2,368,000
Other Long-term Obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		803,000	2,300,000
Accrued Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		1,100,000	274,000
Ostial Solutions, LLC | Developed technology
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Finite-lived Intangible Assets, Fair Value Disclosure					$447,000

Schedule_II_Valuation_and_qual1

Schedule II - Valuation and qualifying accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	($840)		($892)		($464)
Additions Charged to Costs and Expenses	-83	[1]	-376	[1]	-545	[1]
Deduction	30	[2]	428	[2]	117	[2]
Balance at End of Year	-893		-840		-892
Valuation Allowance of Deferred Tax Assets [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	-1,363		-1,225		-361
Additions Charged to Costs and Expenses	-240	[3]	-138	[3]	-864	[3]
Deduction	0		0		0
Balance at End of Year	($1,603)		($1,363)		($1,225)
[1]	We record a bad debt provision based upon historical experience and a review of individual customer balances.
[2]	When an individual customer balance becomes impaired and is deemed uncollectible, a deduction is made against the allowance for uncollectible accounts.
[3]	We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.